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1 Introduction 
 
1.1 Obesity  
Obesity represents a steadily increasing health threat to our society and is a major 
cause of morbidity and mortality. Over the last 10 years, the percentage of overweight 
adults in the United States has increased from 45 to 58% (Fig. 1) (1). This increment in the 
prevalence of overweight and obesity, a trend found not only in adults but also in children, 
has been observed in many other countries of the world (2-4). According to latest 
projections of the World Health Organisation (WHO) 1.6 billion adults are overweight and 
at least 400 million are obese worldwide. These numbers will presumably rise to 2.3 
billion overweight and 700 million obese individuals until the year 2015 (5).  
The underlying cause of excessive weight gain is a continuous imbalance between 
energy intake on one hand, and energy expenditure on the other (6). Enhanced 
susceptibility to obesity is not only attributable to genetic variation but also to a number of 
other factors including a global shift in diet composition towards higher amounts of fat and 
carbohydrates and lower amounts of vitamins, minerals and other micronutrients (7). 
Furthermore, decreased physical activity and a shift towards a sedentary lifestyle 
contribute to the obesity epidemic (8, 9). 
 
 
 
Fig. 1: Prevalence of overweight in the United States from 1991-2001. 
Since 1991, the percentage of overweight adults has risen from 45 to 58%. Of those overweight in 2001, 56% 
were men and 44% were women. Mokdad et al, 2003 (1). 
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The most common measure for defining overweight and obesity is the body mass 
index (BMI) which is assessed by the ratio of body weight in kilogramm (W) and height in 
meters (H) multiplied by itself (W/H2) (10). Individuals with a BMI of 25 to 29.9 kg/m2 
are defined as overweight while obesity is characterized by a BMI of 30 kg/m2 or higher 
(5). Obesity predisposes to a variety of different diseases. It represents an independent risk 
factor for myocardial infarction, stroke, type 2 diabetes mellitus, and certain types of 
cancer (11-13). Adiposity, which is the fraction of total body mass comprised of neutral 
lipid stored in adipose tissue, is closely correlated with important physiological parameters 
such as blood pressure, systemic insulin sensitivity, serum triglyceride and leptin 
concentrations (14-16). Several obesity-related disorders including insulin resistance, 
glucose intolerance, dyslipidemia, hypertension, and coronary artery disease are positively 
correlated with adiposity (15, 17). It has been shown that visceral fat accumulation is more 
closely linked to obesity-associated pathologies than overall adiposity (18). Changes in 
adipose tissue mass are associated with changes in the endocrine and metabolic functions 
of adipose tissue that connect increased adiposity to alterations in systemic physiology. For 
example, the concentration of circulating leptin, the most prominent adipocyte-derived 
hormone, positively correlates with increased adipocyte volume and number (19). Leptin 
functions as an important regulator of energy intake and storage, insulin sensitivity, and 
metabolic rate (20-22). In contrast, adiposity is negatively correlated with plasma 
concentrations of adiponectin, an adipocyte-derived, insulin-sensitizing hormone that 
decreases hepatic gluconeogenesis and increases lipid oxidation in muscle (23-25). 
Visceral fat accumulation belongs to a group of risk factors including high blood 
pressure, high blood glucose, high levels of triglycerides and low levels of high density 
lipoproteins which are subsumed under the term metabolic syndrome (26). These 
conditions predispose for cardiovascular disease (CVD) and type 2 diabetes mellitus 
(T2DM) (27-29).  
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1.2 Diabetes Mellitus 
Since one of the major consequences of excessive weight gain is the development of 
insulin resistance, it is not surprising that an increase in number of overweight and obese 
individuals within a population (Fig. 1) is accompanied by a rise in the occurence of 
diabetes (Fig. 2). Diabetes mellitus is a chronic disease and the sixth leading cause of death 
in the United States. In 2007, a total of 23.6 million US citizens, representing 8% of the 
population, suffered from diabetes. Health care costs, whether assigned to diabetes directly 
or indirectly, were estimated at 174 billion USD for the year 2007 (30). According to the 
WHO 180 million people worldwide suffer from diabetes and these numbers are predicted 
to more than double by 2030. In 2005, 1.1 million people died from diabetes all over the 
world and an increase by more than 50% is projected for the next 10 years (31, 32).  
 
 
 
Fig. 2: Prevalence of diabetes in the United States from 1991-2001. 
The prevalence of people diagnosed with diabetes increased to 7.9% in 2001 from 4.9% in 1990, an increase 
of 61%. In 2001, 3.4% of US adults (2.9% men, 3.8% women) were both obese and had diabetes, an increase 
of 1.4% compared to 1991. Mokdad et al, 2003 (1). 
 
In principal, there are two idiopathic forms of diabetes known as type 1 and 2. Type 
1 diabetes mellitus (T1DM), also termed juvenile diabetes or insulin-dependent diabetes 
(IDDM), is characterized by the loss of insulin-producing β-cells in the Langerhans islets 
of the pancreas as a result of autoimmune reactions (33). T1DM can be treated and 
contained by an insulin replacement therapy and dietary management (34).  
Type 2 diabetes mellitus, formerly known as adult-onset diabetes, is the non-
insulin-dependent (NIDDM) form of diabetes and accounts for 90-95% of all diagnosed 
cases of diabetes (30). This disease develops when chronic overnutrition colludes with 
genetic susceptibility to cause insulin resistance and a relative insulin deficiency of non-
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autoimmune etiology (35, 36). When resistance to the metabolic effect of insulin occurs, 
the pancreas is able to compensate with expansion of β-cell mass and hypersecretion of the 
hormone (37). It is assumed that the ultimate stimulus is nutrient surplus in the blood, 
predominantly glucose and free fatty acids (FFA) (38-40). However, prolonged 
overproduction of insulin leads to progressive detoriation of β-cell function associated with 
apoptosis-driven loss of β-cell mass leading to subsequent progression to a type 2 diabetic 
state (41-43). T2DM is characterized by severe hyperglycemia and altered lipid 
homeostasis (44-46).  
Treatment strategies for T2DM include oral agents such as sulfonylureas, 
biguanides and thiazolidinediones (TZD) which increase insulin secretion, insulin action 
and augment overall insulin sensitivity, respectively (47-50). Interestingly, anti-
inflammatory drugs like salicylates can also improve insulin sensitivity (51, 52). In 
addition, lifestyle changes especially increased exercise and dietary adjustments including 
caloric restriction ameloriate T2DM morbidity (53, 54). In the long-term, diabetes is 
associated with complications such as atherosclerosis, retinopathy, nephropathy, 
neuropathy and impaired wound healing which all impose significant economical 
consequences (55-60). 
 
 
1.2.1 Systemic and Molecular Effects of Insulin Signaling 
Insulin has most potent anabolic effects and promotes the synthesis and storage of 
carbohydrates, lipids and proteins, while inhibiting their degradation and release into the 
circulation (44). It controls energy homeostasis by stimulating glucose uptake in peripheral 
tissues and suppressing the release of stored lipids from adipose tissue (61-64). 
Furthermore, it increases glycolysis and inhibits gluconeogenesis in the liver (65-67).  
The pleiotropic effects of insulin are mediated by binding of the hormone to its 
membrane-bound receptor (68). The insulin receptor (IR) belongs to the family of receptor 
tyrosine kinases and comprises four subunits of which two regulatory α-subunits inhibit the 
two catalytic β-subunits. Upon binding of insulin, the α-subunits undergo a conformational 
change that leads to derepression of the β-subunits which subsequently transphosphorylate 
(69). This facilitates interaction with the phosphotyrosine binding (PTB) domains of 
downstream signaling components (70-73) which localize to the plasma membrane by 
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interaction of their N-terminal Pleckstrin homology (PH) domain with lipid-bound inositol 
phosphates (74, 75).  
There are at least nine known intracellular substrates of the insulin receptor. Four of 
these belong to the insulin receptor substrate (IRS) family (76-78). Others include Grb2-
associated binding protein 1, p60dok, Casitas B-lineage lymphoma (Cbl), adapter protein 
with a pleckstrin homology and a Src homology 2 domain (APS) and isoforms of Shc (79-
81). These molecules serve as docking platforms for Src-homology (SH)-2 domain-
containing proteins such as the regulatory subunit of the phosphatidylinositol-3 kinase 
(PI3K) and the growth factor receptor binding protein (Grb)-2. Subsequent signal 
transduction results in the activation of the PI3K and the Ras/Raf Mitogen-activated 
protein (MAP)-kinase pathways (82-85). 
 
 
 
 
Fig. 3: Insulin signal transduction pathway.  
Binding of insulin to the insulin receptor results in receptor trans-phosphorylation and activation leading to 
the recruitment and subsequent phosphorylation of insulin receptor substrates. This enables the binding of 
SH-2 domain containing proteins, which ultimately leads to the activation of downstream signaling pathways 
such as the PI3K or the Ras/Raf MAPK signaling pathway. (Abbreviations: Akt: Proteinkinase B, APS: 
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adapter protein with a pleckstrin homology and an Src homology 2 domain, CAP: cbl-associated protein,  
ERK: extracellular signal-regulated kinase, FOXO: Forkhead transcription factor , Glut4: glucose transporter 
4, Grb2: growth factor receptor binding protein 2, Gsk3: glycogen synthase kinase 3, IR: insulin receptor, 
IRS: insulin receptor substrate, mTOR: mammalian target of rapamycin, p70S6K: p70 S6 kinase, PI3K: 
phosphatidylinositol-3 kinase, PIP: phosphatidylinositol phosphate, Pdk: phosphoinositide-dependent kinase, 
PKA: Proteinkinase A, PKC: Proteinkinase C, SOS: son of sevenless, Raf: v-raf-leukemia viral oncogene, 
Ras: rat sarcoma) 
 
Activation of the Ras/Raf MAP-kinase pathway leads to cellular proliferation and 
differentiation while no significant effect on the metabolic actions of insulin has been 
observed (86, 87). In contrast, insulin-induced PI3K activation mediates the vast majority 
of metabolic effects of the hormone including glycogen, protein and lipid synthesis, 
inhibition of apoptosis and stimulation of glucose transport. Most of these processes are 
mediated through activation of Protein kinase B/Akt (88-91). However, a PI3K-
independent pathway for the regulation of glucose transport has also been identified (92). 
In this pathway, the insulin receptor directly recruits the adaptor protein APS and the Cbl-
cbl associated protein (93) complex. Tyrosine-phosphorylated Cbl then recruits the CrkII-
C3G complex to lipid rafts, leading to downstream activation of TC10 and ultimately 
resulting in translocation of glucose transporter (GLUT) 4 to the plasma membrane (94-98) 
(Fig. 3).  
 
 
1.3 Obesity, Inflammation and Insulin Resistance 
The nutritional or metabolic state of an organism is closely linked to its immune 
system in a delicate balance. Malnutrition impairs immune processes thereby rendering an 
organism more susceptible to infectious diseases (99, 100). This arises from a reduced 
metabolic support under conditions of infection during which the immune system is highly 
dependent on the mobilization of nutrients and supply with energy to eliminate pathogens 
(101). In contrast, overnutrition i.e. obesity is associated with chronic, low-grade activation 
of the immune system and increased susceptibility to inflammatory diseases (102). This 
can lead to insulin resistance when inflammatory pathways interfere with insulin signaling 
cascades (103).  
The first evidence for the importance of inflammatory signaling in obesity-induced 
insulin resistance was the observation that the pro-inflammatory cytokine tumor necrosis 
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factor (TNF) α is elevated in adipose tissue of obese mice and humans and is capable of 
inducing insulin resistance in vitro (104-106). TNF-α acts via the TNF receptor and 
activates intracellular protein kinases e.g. the inhibitor of nuclear factor (NF) κB kinases 
(IKKs) and c-jun N-terminal kinases (JNKs) (107, 108). Subsequently, these kinases 
mediate inhibitory phosphorylation events on serine (S307) residues of IRS molecules 
(109, 110). S307 phosphorylation of IRS reduces both tyrosine phosphorylation of IRS in 
response to insulin and its ability to associate with the insulin receptor, thus inhibiting 
downstream signaling and insulin action (111, 112). Inhibition or inactivation of IKK or 
JNK in mice has been shown to protect from obesity-induced insulin resistance (51, 52, 
113-115). Aside from TNF-α, a variety of other inflammation-associated factors including 
interleukin (IL) 6, IL-1, IL-8, c-reactive protein (CRP), monocyte chemoattractant protein 
1 (MCP-1, also called CCL2), vascular cell adhesion molecules (VCAMs) and matrix 
metalloproteinases (MMPs) are upregulated in the adipose tissue and/or circulation of 
obese mice and humans and have been linked to obesity and insulin resistance (93, 116-
121).  
In addition to these factors, the obesity-associated increase in circulating free fatty 
acids (FFAs) has been shown to interfere with insulin signaling in target tissues via 
activation of IKK, JNK and protein kinase C (PKC) (122-127). This interference is 
mediated via at least two mechanisms. On one hand, FFAs induce inflammatory signaling 
cascades by activation of toll-like receptors (TLRs). TLRs belong to a family of pattern-
recognition receptors that play a crucial role in activating the pro-inflammatory response 
after contact with microbial pathogens (128). The best characterized member of this 
receptor family is TLR4 which recognizes lipopolysaccharides (LPS), components of the 
bacterial cell wall. Signal transduction after contact with LPS is mediated through 
intracellular binding of myeloid differentiation factor 88 (MyD88) to the Toll/IL-1 receptor 
(TIR) domain of the receptor and subsequent activation of the NFκB pathway. This leads 
to expression of pro-inflammatory cytokines and chemokines and other effectors of the 
innate immune response (129).  
Besides LPS, whose lipid component is sufficient to mediate TLR signaling, 
saturated fatty acids have the full potential to promote TLR4 activation in vitro (130, 131). 
Disruption of TLR4 in mice has been demonstrated to partially protect these animals from 
obesity-induced insulin resistance and substantially reduce the negative effect of systemic 
lipid infusion on glucose metabolism and muscle insulin action (132). In addition to TLR 
signaling, FFA activate inflammatory serine kinases by intermediates of their intracellular 
  Introduction 
-8-   
processing pathways such as β-oxidation in the mitochondria, storage to triglyceride depots 
and conversion into ceramides (133-136). 
Another important aspect of obesity-induced insulin resistance is the development of 
endoplasmatic reticulum (ER) stress. Under normal conditions, the ER is the site of protein 
folding and assembly by chaperones (137). However, obesity generates conditions of 
glucose or nutrient deprivation, inundation with fatty acids or increased expression of 
secretory proteins that elevate the demand on the ER leading to accumulation of unfolded 
or misfolded proteins.  
 
 
 
 
Fig. 4: Potential mechanisms for the inhibition of insulin signal transduction in obesity. 
Obesity increases circulating inflammatory cytokine and free fatty acid concentration. This leads to 
activation of cell surface receptors which then induce serine kinases like c-jun N-terminal kinase (JNK), 
inhibitor of NFkB kinase (IKK) komplex and protein kinase c (PKC) isoforms. These kinases then mediate 
inhibitory serine (S307) phosphorylation events on insulin receptor substrates (IRS) thereby blocking insulin 
action. Additionally, transcription factors nuclear factor kB (NFkB), activator protein (AP) 1 and signal 
transducer and activator of transcription (Stat) activate inflammatory gene expression thereby enhancing 
production and secretion of inflammatory markers and mediators. Furthermore, endoplasmatic reticulum 
(ER) stress and intermediates of fatty acid metabolism may activate stress kinases. (Abbreviations: CR: 
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cytokine receptor, FFA: free fatty acid, FA: fatty acid, IL1R: interleukin-1 receptor, IR: insulin receptor, IRS: 
insulin receptor substrate, LPS: lipopolysaccharide, TLR: toll-like receptor, TNF: tumor necrosis factor, 
TNFR: TNF receptor) 
 
This in turn triggers the unfolded protein response (UPR) which enhances the 
transcription of genes involved in assembly, folding, modification and degradation of 
proteins to normalize ER function (138). It has been suggested that failure of this adaptive 
response leads to activation of various cell death effectors such as Bax, Bak and caspases 
(139-141). Nevertheless, the UPR not only affects gene transcription and pro-apoptotic 
factors but also activates stress kinases like JNK and expression of pro-inflammatory 
cytokines via the IKK/NFκB axis which ultimately induces insulin resistance (142-144). A 
recent study demonstrated that the genetic disruption of x-box protein (XBP) 1, a 
transcription factor that mediates expression of ER chaperones, leads to increased ER 
stress, activation of JNK and induction of insulin resistance via serine-phosphorylation of 
IRS in diet-induced obese mice (138). Furthermore, treatment of diet-induced obese mice 
with orally active chemical chaperones reverses these effects on ER stress and JNK and 
improves tissue insulin sensitivity (145). These findings underline the importance of ER 
stress and inflammatory signals in the development of obesity-induced insulin resistance. 
 
 
1.4 Macrophages  
In general, macrophages belong to the mononuclear phagocyte system which also 
includes monocytes and their lineage-committed precursors (146). The first step of 
macrophage development takes place in the bone marrow where myeloid progenitors 
differentiate into monocytes. Monocytes in turn enter the circulation and give rise to 
tissue-resident macrophage populations throughout the body (147). Recruitment of 
monocytes to peripheral tissues and differentiation into macrophages is enhanced by pro-
inflammatory, metabolic and immune stimuli (148). Macrophages are classically defined 
to belong to the innate immune system and, due to their ubiquitous distribution, represent a 
first line of defense against invading pathogens (149). Their main functions are the 
maintenance of tissue homeostasis and initiation of the inflammatory response. 
Furthermore, macrophages harbor pronounced chemotactic and phagocytotic abilities and 
contribute to tissue remodeling and repair (150). Macrophage dysfunction is associated 
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with a variety of diabetes-associated diseases such as atherosclerosis, retinopathy, 
nephropathy, neuropathy and impaired wound healing (151, 152). 
 
 
1.4.1 The Role of Macrophages in Obesity-induced Insulin Resistance 
In obesity, the adipose tissue is an important initiator of the inflammatory response 
since it not only serves as a storage depot for excess calories, but is also capable of 
secreting fatty acids, hormones, cytokines and chemokines which then act in both 
endocrine and paracrine fashion (153). Although it mainly consists of adipocytes, the 
adipose tissue also contains preadipocytes, endothelial cells and immune cells which all 
reside in the stromal vascular fraction. During expansion of the adipose tissue in obesity, 
local hypoxia occurs due to hypoperfusion with blood vessels. This microhypoxia induces 
activation of JNK and NFκB signaling cascades and increases inflammatory gene 
expression, leading to secretion of chemokines and, ultimately, adipocyte death (154). 
Chemokines that are released into the circulation during these events attract macrophages 
which then surround dead adipocytes for removal of cell debris and tissue remodeling 
(155). In addition, these macrophages secrete pro-inflammatory cytokines and chemokines 
thereby inducing insulin resistance in adjacent adipocytes and recruiting more 
macrophages from the vascularity to the fat tissue (156).  
Accumulation of macrophages in adipose tissue is an important hallmark of 
adiposity, a condition in which these cells represent 40% of the total adipose cell content in 
contrast to only 10% in lean counterparts (157). Conditional disruption of pro-
inflammatory kinases JNK1 and IKKβ specifically in myeloid cells protected mice from 
diet-induced insulin resistance, decreased the inflammatory tone and blocked accumulation 
of macrophages in adipose tissue in different models of obesity (114, 158). Interestingly, 
although JNK1 and IKKβ remained intact in all organs despite immune cells, no effect on 
adiposity was observed in these studies. Furthermore, conventional disruption of MCP-1, 
which is an important chemoattractant for immune cells, or its receptor CCR2, prevented 
the accumulation of macrophages in adipose tissue of obese mice and improved overall 
insulin sensitivity (159, 160). These studies clearly indicate that systemic inflammation 
alone can affect insulin sensitivity and that the obesity-associated inflammatory state is 
mainly mediated through the myeloid compartment of the immune system and infiltration 
of immune cells into adipose tissue. 
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1.4.2 Adipose Tissue Macrophage Heterogeneity 
Macrophages can be divided into at least two subgroups, M1 and M2 (161). M1-
cells are defined as "classically activated" macrophages, which are induced by interferon 
(IFN) γ and LPS. These macrophages secrete pro-inflammatory cytokines (e.g. TNF-α, IL-
6, IL-12) and produce high levels of nitric oxide (NO) via inducible nitric oxide synthase 
(iNOS) expression (162). In addition, they show increased reactivity to fatty acids and 
LPS. M2-cells or "alternatively activated" macrophages are induced by IL-4 or IL-13 and 
display a more anti-inflammatory phenotype since they produce high levels of IL-10 and 
IL-1 decoy receptor and only secrete low levels of pro-inflammatory cytokines. M2 
macrophages are generally involved in tissue repair and remodeling (163).  
Recently, it has been demonstrated that macrophages invading the adipose tissue of 
obese animals exhibit a different polarization compared to the cells identified in the 
adipose tissue of lean animals. Freshly recruited macrophages are positive for surface 
markers F4/80, CD11b and CD11c and have a pronounced pro-inflammatory profile 
showing high reactivity to LPS and FFA allocating them to the M1 subgroup (164). In 
contrast, resident adipose tissue macrophages in lean animals also express F4/80 and 
CD11b surface markers, but lack CD11c expression almost completely. These cells exhibit 
an M2/anti-inflammatory profile showing reduced expression of IL-6, iNOS and CCR2 
(165). Notably, the obesity-induced switch in the adipose tissue macrophage activation 
state is not dependent on the conversion of resident M2 macrophages to an M1 phenotype 
but arises from a localized recruitment of inflammatory macrophage subtypes out of the 
circulation (166). An important mediator of M1 to M2 polarization of macrophages is the 
nuclear receptor peroxisome proliferator-activated receptor (PPAR) γ which acts as a lipid 
sensor (167) and whose conditional disruption in myeloid cells has been shown to impair 
alternative activation of macrophages and predisposes for obesity-induced insulin 
resistance and glucose intolerance (168). Activation of PPARγ in macrophages e.g. by 
treatment with TZDs polarizes towards an M2 phenotype, thus also providing an 
explanation for the beneficial effect of these compounds on insulin sensitivity in humans 
(169). Recently, the importance of M1 vs. M2 macrophages in obesity-induced insulin 
resistance has been demonstrated by Patsouris and colleagues. In this study, ablation of 
CD11c-positive cells in obese, insulin resistant mice lead to a drastic decrease in 
inflammatory marker expression and normalized insulin sensitivity to that of lean controls 
(170). 
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According to these findings, it is clear that activated macrophages infiltrate the 
adipose tissue in obesity. However, another important question asks which signals lead to 
activation of macrophages in this context. Obesity provides an extracellular environment 
that is enriched with lipids, pro-inflammatory cytokines, chemokines and even gut-derived 
bacterial compounds which can activate macrophages (171). Among the receptors 
activated by these signals, TLRs are the most intensively investigated family. Disruption of 
TLR2 or TLR4 or both prevent the activation of inflammation in macrophages by FFA 
(172, 173). In addition to FFA, cytokines derived from expanding adipose tissue, ER stress 
and also microhypoxia, whose central mediator hypoxia inducible factor (HIF) was shown 
to be crucial for the regulation of macrophage function (174), can activate inflammatory 
pathways in these cell types. 
 
 
1.5 Macrophages and Insulin 
Until now, only few studies have been performed to investigate the effect of insulin 
itself on macrophage activation and function. Primary monocytes and macrophages 
express insulin receptors as they were used to study insulin binding affinities and receptor 
turnover in the 1970s (175-177). The functionality of the insulin receptor on monocytes 
was demonstrated first when insulin was shown to modulate Fc receptor expression on 
these cells (178). Furthermore, insulin augments the bacteriocidal properties of 
macrophages against Salmonella typhimurium and enhances their chemotactic activity 
towards pancreatic β-cell islets in vitro (179, 180). Approximately 10 years later, Costa-
Rosa and colleagues further investigated insulin's effect on macrophage key functions. 
They demonstrated that insulin does not affect cell migration, at least in response to 
thioglycolate and Bacille Calmette-Guérin (BCG), but significantly enhances 
phagocytosis, H2O2 production and glucose metabolism in macrophages (181).  
More recent studies demonstrated that insulin induces TNF-α mRNA and protein 
expression in an ERK-dependent manner and promotes survival in a human monocytic 
cell-line (182, 183). Moreover, the same cell-line, when exposed to LPS followed by 
insulin treatment, shows enhanced secretion of TNF-α and IL-1β compared to LPS alone 
(184). The role of insulin in cell survival was also demonstrated in primary murine 
macrophages. Treatment with insulin increased protein levels of anti-apoptotic B-cell 
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lymphoma (Bcl) 2 and induced XBP-1 and 78 kDa glucose response protein (GRP78), 
which are both involved in the UPR (185). 
The concept of insulin's role in macrophage survival was further supported when 
Han et al. demonstrated that in a mouse model of atherosclerosis, transplantation of bone 
marrow from insulin receptor-deficient animals into a low density lipoprotein (LDL) 
receptor-deficient background, leads to advanced lesion formation (186). This was 
ascribed to increased ER stress and apoptosis in IR-deficient macrophages due to elevated 
scavenger receptor A (SRA) expression and enhanced uptake of oxidized LDL. 
Interestingly, our lab demonstrated in a similar study that myeloid cell-autonomous IR-
deficiency decreases formation of atherosclerotic plaques in mice (187). Here, IR-deficient 
primary macrophages displayed unaltered uptake and efflux of cholesterol. Furthermore, 
IR-deficient macrophages exhibited decreased expression and secretion of IL-6 after 
stimulation with LPS indicating a reduced inflammatory response in these cells. 
Taken together, insulin exerts a variety of effects on macrophage function including 
survival, phagocytosis, migration and inflammatory gene expression. However, until 
today, the role of macrophage insulin receptor signaling in obesity-induced insulin 
resistance remains elusive. 
 
 
1.6 Objectives 
To study the role of insulin signal transduction in macrophages in obesity-induced 
insulin resistance, mice with a conditional disruption of the insulin receptor specifically in 
myeloid cells were generated. The aim of this study was to physiologically characterize 
these animals under normal chow and high fat diet. In addition, we sought to study glucose 
metabolism in insulin target tissues by euglycemic-hyperinsulinemic clamp analysis. Also, 
the impact of myeloid cell insulin receptor deficiency on obesity-associated inflammation, 
both locally and systemically, was to be investigated. Furthermore, we wanted to analyze 
the action of insulin in primary macrophages in a cell-autonomous fashion in relation to 
migration/chemotaxis, apoptosis and inflammation. 
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2 Materials and Methods 
2.1 Chemicals 
Size markers for agarose gel electrophoresis (Gene Ruler DNA Ladder Mix) and for 
SDS-PAGE (Prestained Protein Ladder Mix) were obtained from MBI Fermentas, St. 
Leon-Rot, Germany. RedTaq DNA Polymerase and 10 x RedTaq buffer were purchased 
from Sigma-Aldrich, Seelze, Germany. 
 
 
Chemical Supplier 
ε-aminocaproic acid Sigma-Aldrich, Seelze, Germany 
2-Deoxy-D-[1-14C]-Glucose Amersham, Freiburg, Germany 
Acetone KMF Laborchemie, Lohmar, Germany 
Acrylamide Roth, Karlsruhe, Germany 
Agarose (Ultra Pure) Invitrogen, Karlsruhe, Germany 
Amyloglucosidase Roche, Mannheim, Germany 
Aprotinin Sigma-Aldrich, Seelze, Germany 
Benzamidine Sigma-Aldrich, Seelze, Germany 
β-Mercaptoethanol (β-ME) AppliChem, Darmstadt, Germany 
Bovine serum albumin (BSA) Sigma-Aldrich, Seelze, Germany 
BSA essentially fatty acid free Sigma-Aldrich, Seelze, Germany 
Bradford reagent Bio-Rad, München, Germany 
Bromphenol blue Merck, Darmstadt, Germany 
Calcein Invitrogen, Karlsruhe, Germany 
Chloroform Merck, Darmstadt, Germany 
D-[3-3H]-Glucose Amersham, Freiburg, Germany 
Desoxy-Ribonucleotid-Triphosphates (dNTPs) Amersham, Freiburg, Germany 
Dextran sulfate AppliChem, Darmstadt, Germany 
Dimethylsulfoxide (DMSO) Merck, Darmstadt, Germany 
Dithiothreitol (DTT) Boehringer, Mannheim, Germany 
Enhanced Chemiluminscence (ECL) Kit Perbio Science, Bonn, Germany 
Ethanol, absolute AppliChem, Darmstadt, Germany 
Ethidium bromide Sigma-Aldrich, Seelze, Germany 
Ethylendiamine tetraacetate (EDTA) AppliChem, Darmstadt, Germany 
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Fetal Calf Serum (FCS) Gibco BRL, Eggenstein, Germany 
Gelatine Sigma-Aldrich, Seelze, Germany 
Glacial acetic acid Roth, Karlsruhe, Germany 
Glucose DeltaSelect, Pfullingen, Germany 
Glycerol Serva, Heidelberg, Germany 
Hydrochloric acid (37 %) KMF Laborchemie, Lohmar, Germany 
Insulin Novo Nordisk, Bagsværd, Denmark 
Isopropanol Roth, Karlsruhe, Germany 
LaddermanTM DNA Labeling Kit Cambrex Bio Science, Verviers, Belgium 
Leptin Sigma-Aldrich, Seelze, Germany 
Lipopolysaccharide (LPS) Sigma-Aldrich, Seelze, Germany 
MCP-1 Sigma-Aldrich, Seelze, Germany 
Methanol Roth, Karlsruhe, Germany 
Non-essential amino acids Gibco BRL, Eggenstein, Germany 
Palmitate Sigma-Aldrich, Seelze, Germany 
Penicillin/Streptomycin Solution Gibco BRL, Eggenstein, Germany 
Phenol-Chloroform-Isoamyl alcohol AppliChem, Darmstadt, Germany 
Phenylmethylsulfonylfluoride (PMSF) Sigma-Aldrich, Seelze, Germany 
Phosphate buffered saline (PBS) Gibco BRL, Eggenstein, Germany 
Potassium hydroxide Merck, Darmstadt, Germany 
Proteinase K Roche, Mannheim, Germany 
RPMI 1640  Gibco BRL, Eggenstein, Germany 
Salmon sperm DNA Sigma-Aldrich, Seelze, Germany 
Sodium acetate AppliChem, Darmstadt, Germany 
Sodium chloride AppliChem, Darmstadt, Germany 
Sodium dodecyl sulfate AppliChem, Darmstadt, Germany 
Sodium hydroxide AppliChem, Darmstadt, Germany 
Sodium fluoride Merck, Darmstadt, Germany 
Sodium orthovanadate Sigma-Aldrich, Seelze, Germany 
Sodium pyruvate Gibco BRL, Eggenstein, Germany 
Sucrose AppliChem, Darmstadt, Germany 
Tetramethylethylenediamine Sigma-Aldrich, Seelze, Germany 
Thioglycollate Sigma-Aldrich, Seelze, Germany 
Tramadolehydrochloride Grünenthal GmbH, Stolberg, Germany 
Avertin Sigma-Aldrich, Seelze, Germany 
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Trishydroxymethylaminomethane AppliChem, Darmstadt, Germany 
Triton X-100 Applichem, Darmstadt, Germany 
Tween 20 Applichem, Darmstadt, Germany 
Western Blocking Reagent Roche, Mannheim, Germany 
 
 Table 1: Chemicals 
 
 
2.2 Molecular Biology 
Standard methods of molecular biology were performed according to Sambrook and 
Russell (188), unless stated otherwise. 
 
 
2.2.1 Isolation of Genomic DNA 
Mouse tail biopsies were incubated 2-3 hours (h) in lysis buffer (100 mM Tris-HCl 
(pH 8.5), 5 mM EDTA, 0.2% (w/v) SDS, 0.2 M NaCl, 500 µg/ml proteinase K) in a 
thermomixer (Eppendorf, Hamburg, Germany) at 56°C. Peritoneal macrophages were 
incubated in lysis buffer at 56°C overnight. Precipitation was performed by addition of one 
equivalent of isopropanol. After centrifugation and a single washing step with 70% (v/v) 
ethanol, the DNA pellet was dried at room temperature (RT) for 30 minutes and 
resuspended in double distilled water (ddH2O).  
For Southern blot analysis, 100 mg of murine tissue were digested in lysis buffer 
containing 1 g/ml of proteinase K overnight in a thermomixer at 56°C. Samples were 
centrifuged to discard debris and an equal volume of phenol-chloroform-isoamyl alcohol 
mixture ((v/v/v) 25:24:1, saturated with 100 mM Tris (pH 8.0)) was added to the 
supernatant. Following centrifugation, the aqueous phase was transferred to a fresh vial 
and mixed with an equivalent of chloroform. After centrifugation, DNA was precipitated 
from the supernatant as described above and resuspended in TE buffer (10 mM Tris-HCl 
(pH 8), 1 mM EDTA) containing 50 µg/ml RNaseI. 
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2.2.2 Southern Blot Analysis 
10 µg of phenol-chloroform-extracted DNA were digested overnight at 37°C, with 
50 U of NcoI restriction enzyme (MBI Fermentas GmbH, St. Leon-Rot, Germany), and 
separated electrophoretically on a 0.8% (w/v) agarose gel at 60 V. The DNA was 
subsequently transferred to a HybondTM-N+ nylon membrane (Amersham, Braunschweig, 
Germany) by an alkaline capillary transfer (189) and crosslinked to the membrane by 
baking at 80°C for 20 min. A probe was PCR-amplified using customized primers (Table 
2) and labelled with [32P]-dCTP using the LaddermanTM DNA Labeling Kit (TaKaRa; 
Cambrex Bio Science, Verviers, Belgium). Membranes were equilibrated in 2 x SSC and 
then prehybridized at 65°C for 4 h in hybridization solution (1 M NaCl, 1% (w/v) SDS, 
10% (w/v) dextran sulfate, 50 mM Tris-HCl (pH 7.5), 250 µg/ml sonicated salmon sperm 
DNA). The radioactively labelled probe was then added to the prehybridization solution. 
Hybridization of the probe to its corresponding sequence on the nylon membrane was 
performed overnight at 68°C in a rotating cylinder. Unspecifically bound probe was 
removed by washing the membrane initially with 2 x SSC / 0.1 % (w/v) SDS, followed by 
1 x SSC / 0.1% (w/v) SDS, if necessary. All washes were performed at 68°C under gentle 
shaking for 10-20 min. After each wash, the membrane was monitored with a Geiger 
counter and the washes were stopped when radioactivity reached 50 to 200 cps. The 
membrane was then sealed in a plastic bag and exposed to X-ray film (Kodak XAR-5 or 
BioMAX MS; Eastman Kodak) at -80°C. Films were developed in an automatic developer 
(Agfa, Köln, Germany). 
 
 
Probe Primer Sequence (5’-3’) Orientation 
IR NcoI5’ CCATGGGTCCATAACCTATC sense 
IR NcoI3’ AGTGATGAGATGGCTCATTAG antisense 
 
Table 2: Oligonucleotides used to amplify the southern blot probe  
All primer sequences are displayed in 5’-3’ order. Primer orientation is designated “sense” when coinciding 
with transcriptional direction. All primers were purchased from Eurogentec, Cologne, Germany. 
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2.2.3 Quantification of Nucleic Acids 
Nucleic acid concentration was assessed by measuring the sample absorption at 260 
nm with a NanoDrop® ND-1000 UV-Vis Spectrophotometer (Peqlab, Erlangen, Germany). 
An optical density of 1 corresponds to approximately 50 µg/ml of double-stranded DNA, 
40 µg/ml of RNA and 33 µg/ml of ssDNA. The 260/280 nm absorbance ratio was used as 
a measure of purity for nucleic acid samples. A ratio of ~1,8 was accepted as pure DNA 
and a ratio of ~2,0 as pure RNA. 
 
 
2.2.4 Polymerase Chain Reaction (PCR) 
The PCR method (190, 191) was used to genotype mice for the presence of floxed 
alleles or transgenes with customized primers listed in Table 2. Reactions were performed 
in a Thermocycler iCycler PCR machine (Bio-Rad, München, Germany) or in a Peltier 
Thermal Cycler PTC-200 (MJ Research, Waltham, USA). All amplifications were 
performed in a total reaction volume of 25 µl, containing a minimum of 50 ng template 
DNA, 25 pmol of each primer, 25 µM dNTP Mix, 10 x RedTaq reaction buffer and 1 unit 
of RedTaq DNA Polymerase. Standard PCR programs started with 4 minutes (192) 
denaturation at 95°C, followed by 30 cycles consisting of denaturation at 95°C for 45 
seconds (sec), annealing at oligonucleotide-specific temperatures for 30 sec and elongation 
at 72°C for 30 sec and a final elongation step at 72°C for 7 min. PCR-amplified DNA 
fragments were applied to 1% - 2% (w/v) agarose gels (1 x TAE, 0.5 mg/ml ethidium 
bromide) and electrophoresed at 120 V. 
 
 
Primer Sequence (5’-3’) TAnnealing [°C] Orientation 
LysMCre5’ CTC TAG TCA GCC AGC AGC TG 59 sense 
LysMCre3’ ATG TTT AGC TGG CCC AAA TGT 59 antisense 
IR5’ GAT GTG CAC CCC ATG TCT G 58 sense 
IR3’ CTG AAT AGC TGA GAC CAC AG 58 antisense 
IR∆ GGG TAG GAA ACA GGA TGG 58 sense 
 
Table 3: Oligonucleotides used for genotyping  
All primer sequences are displayed in 5’-3’ order. Primer orientation is designated “sense” when coinciding 
with transcriptional direction. All primers were purchased from Eurogentec, Cologne, Germany. 
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2.2.5 RNA Extraction, RT-PCR and Quantitative Realtime PCR 
Total RNA from murine cells and tissues was extracted using the Qiagen RNeasy 
Kit (Qiagen, Hilden, Germany). 1 µg of each RNA sample was reversely transcribed using 
the Eurogentec RT Kit (Eurogentec, Cologne, Germany) according to manufacturer’s 
instructions. The cDNA was subsequently amplified using an ABI Prism 7900HT Fast 
Real-time PCR System (Applied Biosystems, Foster City, USA). 
 
 
Probe Catalogue N° 
Adiponectin Mm00456425_m1 
Bax Mm00432050_m1 
Bcl-2 Mm00477631_m1 
CCl2 Mm00441242_m1 
CCl3 Mm00441258_m1 
F4/80 Mm00802530_m1 
Gusb Mm00446953_m1 
Hprt1 Mm00446968_m1 
IL-6 Mm00446190_m1 
Insr Mm00439693_m1 
Leptin Mm00434759_m1 
Mac-2 Mm00802901_m1 
TNF-α Mm00443258_m1 
 
Table 4: Taqman Gene Expression Assays  
All assays were purchased from Applied Biosystems, Foster City, USA. 
 
Relative expression of Adiponectin, CCl-2, CCl-3, F4/80, Leptin, Mac-1, Mac-2 and TNF-
α mRNA was determined using standard curves based on white adipose tissue cDNA. 
Samples were adjusted for total cDNA content by Glucuronidase beta (Gusb) and 
hypoxanthine guanine phosphoribosyl transferase (Hprt-) 1 mRNA quantitative Realtime 
PCR. Calculations were performed by a comparative method (2-∆∆CT). In brief, the 
amplification plot is the plot of fluorescence versus PCR number. The threshold cycle 
value (Ct) is the fractional PCR cycle number at which the fluorescent signal reached the 
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detection threshold. Therefore, the input cDNA copy number and Ct are inversely related. 
Data were analyzed with the Sequence Detector System (SDS) software version 2.1 (ABI) 
and Ct value was automatically converted to fold change RQ value ((RQ) = 2− (∆∆CT)). The 
RQ values from each gene were then used to compare the gene expression across all 
groups. 
 
 
2.2.6 Protein Extraction 
Cell pellets or snap-frozen tissues were disrupted in lysis buffer (50 mM HEPES 
(pH 7.4), 1% (v/v) Triton X-100, 0.1 M sodium fluoride, 10 mM EDTA, 50 mM sodium 
chloride, 10 mM sodium orthovanadate, 0,1% (w/v) SDS, 10 µg/ml aprotinin, 2 mM 
benzamidine, 2 mM phenylmethylsulfonyl fluoride (PMSF)) by resuspension and gentle 
vortexing or by usage of a polytron homogenizer (IKA Werke, Staufen, Germany), 
respectively. Particulate matter was removed by centrifugation for 1 h at 4°C. The 
supernatant was transferred to a fresh vial and protein concentration was determined using 
a Bradford assay. Protein extracts were diluted to 5 mg/ml with lysis buffer and 4 x SDS 
sample buffer (125 mM Tris-HCl (pH 6.8), 5% (w/v) SDS, 43.5% (w/v) glycerol, 100 mM 
DTT, and 0.02% (v/v) bromophenol blue), incubated at 95°C over 5 min and stored at -
80°C. 
 
 
2.2.7 SAPK/JNK Kinase Assay 
A c-Jun fusion protein linked to agarose beads (SAPK/JNK Kinase assay #9810; 
Cell Signaling, Danvers, MA, USA) was used to pull down SAPK/JNK enzyme from liver 
and skeletal muscle protein extracts. Immunoprecipitation was performed by overnight 
incubation at 4°C. After two washes with lysis buffer and kinase buffer, 200 µM ATP was 
supplemented to the precipitate. The phosphorylation reaction was carried out at 30°C and 
stopped after 30 min by addition of 4 x SDS sample buffer. Detection of phospho-c-Jun by 
western blot analysis was used to measure SAPK activity. 
 
 
  Materials and Methods 
-21-   
2.2.8 Western Blot Analysis 
Frozen protein extracts were thawed at 95°C for 5 min, then separated on 10-15% 
(v/v) SDS polyacrylamide gels (193) and blotted onto PVDF membranes (Bio-Rad, 
München, Germany). Membranes were then incubated with 1% (v/v) blocking reagent 
(Roche, Mannheim, Germany) for 1 h at RT. Subsequently, primary antibodies (Table 5) 
diluted in 0.5% (v/v) blocking solution were applied overnight at 4°C. PVDF membranes 
were then washed four times for 5 min with 1 x TBS/0.01 (v/v) Tween. After 1 h 
incubation at RT with the respective secondary antibodies, membranes were washed 4 
times for 10 min with 1 x TBS/0.01 (v/v) Tween, rinsed in 1 x TBS, incubated for 1 min in 
Pierce ECL Western Blotting Substrate (Perbio Science, Bonn, Germany), sealed in a 
plastic bag and exposed to chemiluminescence film (Amersham, Braunschweig, 
Germany). Films were developed in an automatic developer. 
 
 
Antibody Catalogue N° Distributor Dilution 
Actin A5441 Sigma Aldrich, Seelze, Germany 1:10000 
Akt 9272 Cell Signaling, Danvers, MA, USA 1:1000 
p-Akt (Ser473) 9271 Cell Signaling, Danvers, MA, USA 1:1000 
p-c-jun (Ser63) 9810 (101) Cell Signaling, Danvers, MA, USA 1:1000 
IRβ (C-19) sc-711 Santa Cruz, Heidelberg, Germany 1:200 
SAPK/JNK 9252 Cell Signaling, Danvers, MA, USA 1:1000 
 
Table 5: Primary antibodies used for western blot analysis  
All respective secondary antibodies were purchased from Sigma Aldrich, Seelze, Germany, and used in a 
1:1000 dilution. 
 
 
2.2.9 Gelatin Zymography 
Cell culture supernatants were purified from lower molecular weight proteins (<50 
kDa) by centrifugation through Microcon® YM-50 Centrifugal Filter Units (# 42415, 
Millipore, Billerica, MA, USA) for 10 minutes at RT. After determination of the protein 
concentration by a Bradford assay, 10 µg total protein were diluted with 4xSDS sample 
buffer (100 mM Tris, 10% (v/v) glycerol, 0.5% (w/v) SDS, 0.05% (w/v) bromophenol 
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blue) and separated on a 10% (v/v) SDS polyacrylamide gel (containing 0.1 mg/ml (w/v) 
gelatine) at 20 mA with 1xSDS running buffer (3 g/l (w/v) Tris base, 14.4 g/l (w/v) 
glycine, 1 g/l (w/v) SDS, pH 8.3 . Subsequently, the gel was soaked in 2.5% (v/v) Triton 
X-100 for 1h at RT. After three fast washing steps with ddH2O, the gel was transferred to 
MMP activation buffer (50 mM Tris-HCl, 5 mM CaCl2, pH 8) and incubated at 37°C 
overnight in a humidified chamber to carry out the digestion reaction. Following three 5 
min washes with ddH2O, the gel was stained with 2.5 g/l (w/v) Coomassie brilliant-blue R-
250 for 1 h at RT. Levels of gelatinolytic activity were revealed by destaining with 40% 
(v/v) methanol until the bands appeared clearly, then the gel was wrapped in plastic foil 
and scanned on a Canon Canoscan 8800F. 
 
 
2.2.10 ELISA 
Mouse insulin (Mouse/Rat Insulin ELISA; Crystal Chem, Downers Grove, IL, 
USA), leptin (ACTIVE® Murine Leptin ELISA; Diagnostics Systems Laboratories, 
Webster, TX, USA), TNF-α (Quantikine Mouse TNF-alpha/TNFSF1A ELISA; R&D 
Systems, Wiesbaden, Germany), IL-6 (Quantikine Mouse IL-6 ELISA; R&D Systems, 
Wiesbaden, Germany), adiponectin (Quantikine Mouse Adiponectin/Acrp30 ELISA; R&D 
Systems, Wiesbaden, Germany) and MMP-9 (Quantikine Mouse MMP-9 (total) ELISA; 
R&D Systems, Wiesbaden, Germany) concentration in serum or cell culture supernatant 
was determined using mouse standards according to manufacturer’s guidelines and 
measured on a Precision Microplate Reader (Emax; Molecular Devices GmbH, München, 
Germany). 
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2.3 Cell Culture and Tissue Analysis 
 
2.3.1 Preparation of L-cell Conditioned Medium 
L929 fibroblasts were seeded on 175 cm² tissue culture flasks in 50 ml DMEM 
(supplemented with 10% (v/v) heat inactivated FCS, 1% (v/v) glutamine, 1% (v/v) 
penicillin-streptomycin). After confluency was reached, 50 ml fresh medium was added to 
the flasks and cells were incubated without further medium exchange for 14 days at 37°C 
and 5% CO2. At the end of the incubation period, medium from different flask was pooled, 
sterile-filtered through a 0.22 µm membrane and aliquoted to 50 ml Falcon tubes. L-cell 
conditioned medium (LCM) was stored at -80°C until use. 
 
 
2.3.2 Preparation of Palmitic Acid Media 
Preparation of 20% BSA: Essentially fatty acid free bovine serum albumin (20% 
(w/v) BSA, # A6003, Sigma-Aldrich, Seelze, Germany) was layered on top of PBS and 
allowed to percolate overnight at 4°C without stirring. After sterile filtering into aliquots, 
fatty acid free BSA was stored at 4°C until the experiment. 
Preparation of 20 mM palmitic acid: Palmitic acid solution was prepared freshly 
before each experiment. 15 ml NaOH (0,01 N) were warmed to 70°C. Subsequently, 84 
mg palmitic acid (# P5585, Sigma-Aldrich, Seelze, Germany) were added and incubated 
for 20-30 min at 70°C. During the incubation period, 50-100 µl aliquots of 1 N NaOH 
were added and the mixture was vortexed several times until the solution cleared. 
Preparation of palmitic acid medium: Complexing was performed immediately 
after palmitic acid was dissolved completely. 0.5 ml of 20 mM palmitic acid solution were 
added to 1.65 ml prewarmed (37°) 20% fatty acid free BSA by vortexing at lowest speed 
without introducing any bubbles. Complexes were added immediately to 17.85 ml of 
prewarmed (37°C) RPMI 1640 (supplemented 1% (v/v) glutamine and 1% (v/v) penicillin-
streptomycin). Palmitic acid medium (500 µM plamitic acid, 250 µM BSA) was then filter 
sterilized through a 0.22 µm membrane and stored at 4°C for up to one week.  
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2.3.3 Differentiation of Murine Bone Marrow to Macrophages 
Bone marrow cells were plated at a concentration of 1-2*106 cells/ml in RPMI 
1640 (Invitrogen GmbH, Karlsruhe, Germany; supplemented with 10% (v/v) heat 
inactivated FCS, 1% (v/v) glutamine, 1% (v/v) penicillin-streptomycin and 10% (v/v) 
LCM) on 15 cm bacterial petridishes. After 6-8 days, medium was renewed followed by 
further incubation until day 10. Adherent cells were removed from the plates with 
TrypLE™ Express (Gibco BRL, Eggenstein, Germany), counted and seeded for further 
experiments in RPMI 1640 with LCM. Preceding all the experiments, cells were washed 
two times with sterile PBS and, if stimulated with insulin, serum-starved for 16-20 h. 
 
 
2.3.4 Culture of Primary Murine Macrophages 
Cells were plated at a density of 1*106/ml on tissue culture dishes (Greiner Bio-One 
GmbH, Frickenhausen, Germany) in RPMI 1640 (supplemented with 10% (v/v) heat 
inactivated FCS, 1% (v/v) glutamine, 1% (v/v) penicillin-streptomycin) and were allowed 
to adhere overnight at 37°C, 5% CO2 and 95% humidity. On the next day, adherent cells 
were washed once with PBS followed by further incubation in RPMI 1640. Preceding all 
the experiments, cells were washed two times with sterile PBS and, if stimulated with 
insulin, serum-starved for 16-20 h. 
 
 
2.3.5 Detection of Apoptotic Cells by TUNEL Assay 
For assessment of apoptosis in primary macrophages, the DeadEnd™ Fluorometric 
TUNEL system (# G3250, Promega Corporation, Madison, WI, USA) was used. The 
protocol for adherent cells was carried out according to the manufacturer's instructions. 
Initially, cells were grown directly on glass cover slips in 6-well tissue culture dishes. 
After a 24 h stimulation period, cells were fixed by incubation in 4% (w/v) 
paraformaldehyde (PFA) for 20 min at 4°C. After two washing steps with PBS, cells were 
permeabilized with 0.2% (v/v) Triton X-100 in PBS for 5 min at RT. Following two 
additional washing steps with PBS, equilibration buffer was added to the slides and 
incubated for 10 min at RT. After removal of equilibration buffer, incorporation of 
fluorescein-12-dUTP by rTdT enzyme was carried out at 37°C in the dark for 60 min. The 
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reaction was stopped by addition of 2x SSC and after three washing steps with PBS, slides 
were mounted with Vectashield DAPI medium (# H-1200, Vector Laboratories Inc, 
Burlingame, CA, USA) and analyzed under a fluorescence microscope. Quantification of 
DAPI- and FITC-positive cells was performed using AxioVision 4.2 (Carl Zeiss 
MicroImaging GmbH, Oberkochen, Germany). 
 
 
2.3.6 Boyden Chamber Analysis 
General design: In a Boyden Chamber, two compartments are separated by a 
porous membrane through which cells can migrate (Fig. 5).  Chemotactic gradients can be 
set up by placing different concentrations of the putative chemoattractant in the upper and 
lower chambers.  The use of this chamber requires that the cells under test have to move in 
three dimensions and are able to squeeze through the pores (5-10 µm diameters) of the 
particular filter.  The Boyden chamber is reproducible and the chemokinetic, chemotactic 
response easy to quantify. 
 
 
Fig. 5: Experimental design of the Boyden Chamber Analysis. 
Two isolated compartments are seperated by a porous membrane (pore size dependent on cell type). The 
lower compartment contains medium substituted with a chemoattractant (e.g. MCP-1). The medium in the 
upper compartment is the same as in the lower compartment but lacks the chemoattractant. Motile cells are 
placed into the upper compartment and migrate against (arrow) the concentration gradient into the lower 
compartment. 
 
Experimental setup: A ChemoTx® Chemotaxis System ( Neuro Probe Inc., 
Gaithersburg, MD, USA) comprised of a 96-well inner plate coated with a partially 
hydrophobic polycarbon filter (pore size 5 µm; upper compartment) and a base plate 
(lower compartment). The cell suspension can be loaded directly onto the membrane. 
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Preparation of cells: The chemotaxis assay was carried out with bone marrow-
derived macrophages of control and IR∆myel mice. Macrophages were lifted from the 
culture dish by gentle scraping. After two washing steps with PBS, cells were icubated in 2 
ml of PBS (supplemented with 3µM Calcein, Molecular Probes/Invitrogen Corp., 
Karlsruhe, Germany) for 20 min at 37°C. Following two additional washing steps with 
PBS, cells were resuspended in incubation buffer (RPMI 1640 supplemented with 10% 
(v/v) heat inactivated FCS, 1% (v/v) glutamine) and cell number was adjusted to 5x106 
cells/ml. 
Assay procedure and analysis: The chemoattractant was dissolved in incubation 
buffer and added to the lower compartments in the desired concentration. Incubation buffer 
without chemoattractant was used as a negative control (random migration). 29 µl of the 
cell suspension were loaded onto the membrane and chemotaxis was carried out at 37°C in 
a humidified chamber. After a migration period of 120 min, the inner plate was removed 
and cells on the upper surface of the filter were detached with a rubber scraper. Green 
fluorescence of adherent cells on the lower surface was detected with a Cytofluor analyser 
(Filter: excitation 485 nm, emission 530 nm; Global Medical Instrumentation Inc., 
Ramsey, MN, USA). Data was collected in triplicates for three independent exeriments. 
 
 
2.3.7 Histological Analysis and Immunohistochemistry 
 White adipose tissue of diet-induced obese Control and IR∆myel mice was dissected, 
fixed overnight in 4% (w/v) PFA and then embedded for paraffin sections. Subsequently, 7 
µm thin sections were deparaffinized and stained with hematoxylin and eosin (H&E) for 
general histology or with Mac-2/Galectin-3 antibody (#CL8942AP; Cedarlane 
Laboratories Ltd, Burlington, ON, Canada) for detection of adipose tissue macrophages. 
Immunohistochemistry was performed as previously described (155). Quantification of 
adipocyte size and Mac-2-positive area was performed using AxioVision 4.2 (Carl Zeiss 
MicroImaging GmbH, Oberkochen, Germany). 
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2.4 Mouse Experiments 
 General animal handling was performed as described by Hogan (194) and Silver 
(195). 
 
 
2.4.1 Animals 
 Mice were housed in a virus-free facility at 22-24°C on a 12 h light/ 12 h dark cycle 
with the light on at 6 a.m. and were either fed a normal chow diet (NCD; Teklad Global 
Rodent 2018; Harlan Winkelmann GmbH, Borchen, Germany) containing 53.5% (w/v) 
carbohydrates, 18.5% (w/v) protein and 5.5% (w/v) fat or a high fat diet (HFD; C1057; 
Altromin GmbH, Lage, Germany) containing 32.7% (w/v) carbohydrates, 20% (w/v) 
protein, and 35.5% (w/v) fat (55.2% of calories from fat). All animals had access to water 
ad libitum. Food was only withdrawn if required for an experiment. At the end of the study 
period, animals were sacrificed by CO2 anesthesia or cervical dislocation. All animal 
procedures and euthanasia were reviewed by the animal care committee of the University 
of Cologne, approved by local government authorities (Bezirksregierung Köln) and were 
in accordance with National Institutes of Health guidelines. 
 
 
2.4.2 IR∆myel mice 
 To disrupt the insulin receptor allele specifically in myeloid cells, mice 
homozygous for the loxP-flanked insulin receptor allele (IRflox/flox) (196) were bred with 
mice homozygous for the LysMCre transgene (197). LysMCre+/-IRflox/wt mice were 
further crossed with IRflox/flox mice to achieve homozygosity for the loxP-flanked allele. 
Breeding colonies were maintained by mating IRflox/flox (30) mice and LysMCre +/- 
IRflox/flox mice (IR∆myel). All metabolic experiments were carried out with male mice 
backcrossed for at least 10 generations onto a C57BL/6 background. 
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2.4.3 Body Weight and Blood Glucose Levels 
 Body weight and blood glucose levels were monitored weekly and at 20 weeks of 
age, respectively. Blood glucose values were determined from whole venous blood using 
an automatic glucose monitor (GlucoMen® GlycÓ; A. Menarini Diagnostics, Neuss, 
Germany). 
 
 
2.4.4 Glucose and Insulin Tolerance Test 
 Glucose tolerance tests (GTT) were performed on animals that had been fasted 
overnight for 16 hours. Insulin tolerance tests (ITT) were performed on random fed mice. 
Animals were injected with either 2 g/kg body weight of glucose or 0.75 U/kg body weight 
of human regular insulin into the peritoneal cavity. Glucose levels were determined in 
blood collected from the tail tip immediately before and 15, 30 and 60 minutes after the 
injection, with an additional value determined after 120 minutes for the GTT. 
 
 
2.4.5 Isolation of Adipocytes and Stromal Vascular Fraction 
Animals were sacrificed and subcutaneous and epididymal fat pads were removed 
under sterile conditions. Adipocytes were isolated by collagenase (1 mg/ml) digestion for 
45 min at 37°C in DMEM/Ham’s F-12 1:1 (DMEM/F12) containing 0.1% (w/v) BSA. 
Digested tissues were filtered through sterile 150 µm nylon mesh and centrifuged at 250 x 
g for 5 min. The floating fraction consisting of pure isolated adipocytes was then removed 
and washed three more times before proceeding to experiments. The pellet, representing 
the stromal vascular fraction containing preadipocytes, macrophages and other cell types, 
was resuspended in erythrocyte lysis buffer consisting of 154 mM NH4Cl, 10 mM KHCO3, 
and 0.1 mM EDTA for 10 min. 
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2.4.6 Isolation of Primary Peritoneal Macrophages 
8-20 week old IR∆myel mice or control mice were injected intreaperitoneally with 2 
ml thioglycollate medium (4% in PBS (w/v)) to induce a sterile peritonitis. On day 4 post 
injection, the animals were sacrificed by CO2 anesthesia and cells were collected by 
peritoneal lavage with sterile PBS. Following centrifugation, cells were resuspended in 
erythrocyte lysis buffer for 3 min at RT. After one additional wash with PBS, cells were 
resuspended in RPMI 1640 (supplemented with 10% (v/v) heat inactivated FCS, 1% (v/v) 
glutamine, 1% (v/v) penicillin-streptomycin) and live cells were counted in 4% (w/v) 
trypan blue. Cell numbers were adjusted to 1*106/ml and stored on ice for further 
experiments. 
 
 
2.4.7 Isolation of Murine Bone Marrow  
8-20 week old mice were sacrificed by CO2 anesthesia, rinsed in 70% (v/v) ethanol 
and femurs and tibias were dissected. After removal of all muscle tissue, bones were cut at 
the ends and bone marrow was flushed with a 26 G needle in sterile, ice-cold PBS. After 
dispersion and resuspension with the same needle, cells were spinned down at 1.200 rpm 
for 5 min at 4°C. Cells were resuspended in erythrocyte lysis buffer and incubated for 3 
min at RT. After one additional wash with PBS, cells were resuspended in RPMI 1640 
(supplemented with 10% (v/v) heat inactivated FCS, 1% (v/v) glutamine, 1% (v/v) 
penicillin-streptomycin and 10% (v/v) LCM) and live cells were counted in 4% (w/v) 
trypan blue. Cell numbers were adjusted to 1*106/ml and stored on ice for further 
experiments. 
 
 
2.4.8 Glucose Transport 
For the determination of glucose transport, isolated adipocytes from the fat depots 
were stimulated with 0.1, 1, 10 and 100 nM insulin for 30 min then incubated for 30 min 
with 3 µM U-14C-glucose. Immediately after incubation, adipocytes were fixed with osmic 
acid, incubated for 48 hours at 37°C and radioactivity was quantified after the cells had 
been decolorized (198).  
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2.4.9 Hyperinsulinemic-euglycemic Clamp Studies 
 Catheter Implantation: At the age of 16-20 weeks, male mice were anesthetized by 
intraperitoneal injection of avertin and adequacy of the anesthesia was ensured by the loss 
of pedal reflexes. A Micro-Renathane catheter (MRE 025; Braintree Scientific Inc., MA, 
USA) was inserted into the right internal jugular vein, advanced to the level of the superior 
vena cava, and secured in its position in the proximal part of the vein with 4-0 silk; the 
distal part of the vein was occluded with 4-0 silk. After irrigation with physiological saline 
solution, the catheter was filled with heparin solution and sealed at its distal end. The 
catheter was subcutaneously tunneled, thereby forming a subcutaneous loop, and 
exteriorized at the back of the neck. Cutaneous incisions were closed with a 3-0 silk suture 
and the free end of the catheter was attached to the suture in the neck as to permit the 
retrieval of the catheter on the day of the experiment. Mice were intraperitoneally injected 
with 1 ml of saline containing 15µg/g body weight of tramadolhydrochloride and placed 
on a heating pad in order to facilitate recovery. 
Clamp Experiment: Only mice that had regained at least 90% of their preoperative 
body weight after 6 days of recovery were included in the experimental groups. After 
starvation for 15 hours, awake animals were placed in restrainers for the duration of the 
clamp experiment. After a D-[3-3H]Glucose (Amersham Biosciences, UK) tracer solution 
bolus infusion (5 µCi), the tracer was infused continuously (0.05 µCi/min) for the duration 
of the experiment. At the end of the 40-minute basal period, a blood sample (50 µl) was 
collected for determination of the basal parameters. To minimize blood loss, red blood 
cells were collected by centrifugation and reinfused after being resuspended in saline. 
Insulin (human regular insulin; NovoNordisc Pharmaceuticals, Inc., NJ, USA) solution 
containing 0.1% (w/v) BSA (Sigma-Aldrich, Germany) was infused at a fixed rate (4 
µU/g/min) following a bolus infusion (40 µU/g). Blood glucose levels were determined 
every 10 minutes (B-Glucose Analyzer; Hemocue AB, Sweden) and physiological blood 
glucose levels (between 120 and 150 mg/dl) were maintained by adjusting a 20% glucose 
infusion (DeltaSelect, Germany). Approximately 60 minutes before steady state was 
achieved, a bolus of 2-Deoxy-D-[1-14C]Glucose (10 µCi, Amersham) was infused. Steady 
state was ascertained when glucose measurements were constant for at least 30 min at a 
fixed glucose infusion rate and was achieved within 100 to 130 min. During the clamp 
experiment, blood samples (5 µl) were collected after the infusion of the 2-Deoxy-D-[1-
14C]Glucose at the time points 0, 5, 15, 25, 35 min etc. until reaching the steady state. 
During the steady state, blood samples (50 µl) for the measurement of steady state 
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parameters were collected. At the end of the experiment, mice were killed by cervical 
dislocation, and brain, liver, WAT and skeletal muscle tissue were dissected and stored at -
20°C.  
Assays: Plasma [3-3H]Glucose radioactivity of basal and steady state samples was 
determined directly after deproteinization with 0.3 M Ba(OH)2 and 0.3 M ZnSO4 and also 
after removal of 3H2O by evaporation, using a liquid scintillation counter (Beckmann, 
Germany). Plasma Deoxy-[1-14C] Glucose radioactivity was directly measured in the 
liquid scintillation counter. Tissue lysates were processed through Ion exchange 
chromatography columns (Poly-PrepR Prefilled Chromatography Columns, AGR1-X8 
formate resin, 200-400 mesh dry; Bio Rad Laboratories, CA, USA) to separate 2-Deoxy-
D-[1-14C]Glucose (2DG) from 2-Deoxy-D-[1-14C]Glucose-6-Phosphate (2DG6P).  
Calculations: Glucose turnover rate (mg×kg-1×min-1) was calculated as the rate of 
tracer infusion (dpm/min) divided by the plasma glucose-specific activity (dpm/mg) 
corrected for body weight. HGP (mg×kg-1×min-1) was calculated as the difference between 
the rate of glucose appearance and glucose infusion rate. In vivo glucose uptake for each 
tissue (nmol×g-1×min-1) was calculated based on the accumulation of 2DG6P in the 
respective tissue and the disappearance rate of 2DG from plasma as described previously 
(199). 
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2.5 Computer Analysis 
 
2.5.1 Densitometrical Analysis 
 Protein expression was assessed by western blot analysis and bands were measured 
in intensity per mm2 using the Quantity One Software (Bio-Rad, München, Germany). 
After background subtraction, each sample was normalized to an internal loading control. 
Average protein expression of control mice was set to 100% and compared to protein 
expression of knockout animals unless stated otherwise. 
 
 
2.5.2 Statistical Methods 
 Data sets were analyzed for statistical significance using a two-tailed unpaired 
student’s t test. All p values below 0.05 were considered significant. 
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3 Results 
 
3.1 Myeloid Cell-specific Disruption of the Insulin Receptor 
The lysozyme M gene is expressed specifically in cells of the myeloid lineage (200). 
Crossing mice carrying a loxP-flanked allele with mice containing a targeted insertion of 
the cre cDNA into the endogenous lysozyme M locus has been shown to promote efficient 
disruption of loxP-flanked alleles in these cell types (201). Clausen et al. reported a 
deletion-efficiency of 83-98% in mature macrophages and of 100% in granulocytes. 
To disrupt the insulin receptor allele specifically in myeloid cells (IR∆myel), mice 
homozygous for the loxP-flanked insulin receptor allele (IRflox/flox) and heterozygous for a 
Cre recombinase under the control of the lysozyme M promotor (LysMCre) were 
generated.  
To analyze recombination of the loxP-flanked fourth exon of the insulin receptor 
allele, bone marrow of control mice and IR∆myel mice was first isolated and differentiated 
in vitro into macrophages. Southern blot analysis was performed with genomic DNA from 
the resulting cell population. As shown in Fig. 6, transgenic expression of the Cre cDNA 
under the control of the lysozyme M promotor lead to a recombination efficiency of ~90% 
in these cells. 
 
 
Fig. 6: Southern blot analysis of the insulin receptor allele in macrophages. 
(a) Southern blot analysis of genomic DNA isolated from bone marrow-derived macrophages (BMDM) from 
control mice and IR∆myel mice (b) Densitometrical quantification of the deleted versus the floxed allele band 
in macrophages of IR∆myel mice. (flox = loxP-flanked allele band (2.5 kb), ∆ = deleted allele band (5 kb); All 
data are presented as mean ± SEM; *** p ≤ 0,001; n = 3 vs. 3) 
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Furthermore, bone marrow-derived macrophages were analyzed for expression of 
insulin receptor mRNA by realtime PCR. As depicted in Fig. 7, expression of the insulin 
receptor mRNA was reduced by ~80% in cells from IR∆myel mice compared to control 
mice. 
 
 
Fig. 7: Insulin receptor mRNA expression in macrophages. 
Insulin receptor mRNA expression was assessed by quantitative realtime PCR in bone marrow-derived 
macrophages from control and IR∆myel mice; Hprt1 was used as endogenous control; (All data are presented 
as mean ± SEM; *** p ≤ 0,001; n = 4 vs 4) 
 
To exclude the possibility that the residual mRNA expression detected by realtime 
PCR analysis might lead to significant amounts of insulin receptor protein expression, 
western blot analysis was performed. Analysis of peritoneally-elicitid macrophages 
demonstrated the complete absence of the insulin receptor protein on these cells (Fig. 8). 
However, as depicted in Fig. 9, protein expression of the insulin receptor was robust and 
unchanged in insulin target tissues of IR∆myel mice compared to control mice.  
 
 
Fig. 8: Insulin receptor protein expression in macrophages.  
Western blot analysis of insulin receptor β subunit (IR-β) and protein kinase B/Akt (loading control) 
expression in peritoneal macrophages of control mice and IR∆myel mice. 
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Fig. 9: Insulin receptor protein expression in insulin target tissues is unchanged in IR∆myel mice. 
Western blot analysis of insulin receptor β subunit (IR-β) and protein kinase B/Akt (loading control) 
expression. Proteins were extracted from brain, heart, liver, pancreas, white adipose tissue (WAT) and 
skeletal muscle (SM) of control mice and IR∆myel mice. 
 
In summary, conditional gene targeting using the lysozyme M promotor to drive Cre 
expression leads to efficient and specific depletion of the insulin receptor in peritoneal and 
bone marrow-derived macrophages without affecting metabolically relevant tissues, such 
as brain, liver and skeletal muscle. 
 
 
3.2 The Effect of Myeloid Cell-restricted Insulin Receptor 
Deficiency on Diet-induced Obesity 
To investigate the impact of myeloid cell-restricted insulin receptor deficiency on 
diet-induced obesity, control mice and IR∆myel mice were fed either a normal chow (NCD) 
or were exposed to a high fat diet (HFD) for 12 weeks. Under NCD both groups exhibited 
indistinguishable growth curves reaching approximately 30 g body weight after 16 weeks 
(Fig. 10a). When exposed to a HFD control mice and IR∆myel mice significantly gained 
weight over animals exposed to NCD. However, both animal groups gained weight to a 
similar extent with an average maximum of 45 g after 16 weeks of age (Fig. 10b). 
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Fig. 10: IR∆myel mice exhibit normal weight gain upon normal chow diet and high fat feeding.  
(a) Body weight curves of control mice and IR∆myel mice exposed to normal chow diet (NCD). Weight gain 
was monitored from the age of 4 to 16 weeks. (b) Body weight curves of control mice and IR∆myel mice 
exposed to HFD. Weight gain was monitored from the age of 4 to 16 weeks. From week 6 onwards, exposure 
to HFD led to a significantly higher average weight compared to NCD. (All data are presented as mean ± 
SEM; NCD n = 15 vs 14; HFD n = 30 vs 30) 
  
In accordance, epididymal fat pad mass was drastically increased upon high fat 
feeding, but unchanged between groups (Fig. 11a). An increase of circulating leptin is 
positively correlated with obesity thereby representing an important indicator for the 
degree of adiposity. Accordingly, serum leptin concentrations were significantly increased 
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after 12 weeks of HFD in control mice and IR∆myel mice compared to lean animals (Fig. 
11b) while no difference was observed between both genotypes. 
 
 
Fig. 11: IR∆myel mice show normal high fat diet-induced increase in epididymal fat pad mass and 
circulating leptin concentration.  
(a) Epididymal fat pad mass in control mice and IR∆myel mice. Animals were dissected after 16 weeks on 
either NCD or HFD and adipose tissue weight was measured. (b) Serum leptin concentrations in control mice 
and IR∆myel mice were determined by ELISA. Serum was isolated after 16 weeks of age on either NCD or 
HFD. (NCD n = 11 vs 10; HFD n = 10 vs 10; All data are presented as mean ± SEM)  
 
Taken together, these results indicate that myeloid cell-restricted insulin resistance 
does not affect the development of obesity upon high fat feeding. 
 
 
3.3 The Effect of Myeloid Cell-restricted Insulin Receptor 
Deficiency on Obesity-induced Insulin Resistance 
Severe obesity is strongly associated with hyperglycemia and hyperinsulinemia. 
These two parameters represent important indicators for reduced insulin sensitivity or even 
insulin resistance. To investigate the effect of myeloid cell-autonomous insulin signaling 
on obesity-induced insulin resistance, glucose metabolism of IR∆myel mice was analyzed. 
Fasted blood glucose levels and insulin levels were determined as a first measure of 
glucose homeostasis in these animals (Fig. 12a, b). On NCD, both genotypes displayed 
average fasted blood glucose concentration of ~60 mg/dl and average fasted serum insulin 
concentration of ~2 pg/ml after 16 weeks of age. Surprisingly, IR∆myel mice on HFD had 
significantly reduced fasted blood glucose compared to control mice although both groups 
clearly developed hyperglycemia. Consistently, fasted serum insulin levels were 
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significantly reduced in obese IR∆myel mice compared to control mice while no difference 
was observed under NCD. 
 
 
Fig. 12: Diet-induced obese IR∆myel mice exhibit significantly reduced fasted blood glucose and insulin 
levels. 
Fasted blood glucose concentration (a) and fasted insulin concentration (b) of 16 week old control mice and 
IR∆myel mice fed either NCD or HFD. (All data are presented as mean ± SEM; NCD n = 11 vs 10; HFD n = 
10 vs 10; **p ≤ 0.01) 
 
After 16 weeks on either NCD or HFD, control mice and IR∆myel mice were 
challenged in a glucose tolerance test (GTT, Fig. 13a). While lean mice (NCD) of both 
groups responded identically to an exogenous glucose challenge, IR∆myel mice fed a high 
fat diet performed significantly better than control mice. Also, during insulin tolerance 
testing (ITT, Fig. 13b), diet-induced obese IR∆myel mice displayed significantly higher 
insulin sensitivity than their littermate controls. 
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Fig. 13: Obese IR∆myel mice exhibit increased glucose tolerance and insulin sensitivity. 
(a) GTT analysis was performed with 16 week old control mice and IR∆myel mice fed either NCD or HFD for 
16 weeks. (NCD n = 6 vs 7; HFD n = 20 vs 20). (b) ITT analysis was performed with 16 week old control 
mice and IR∆myel mice fed either NCD or HFD. (All data are presented as mean ± SEM; NCD n = 6 vs 5; 
HFD n = 14 vs 13; *p ≤ 0.05; ***p ≤ 0.001 HFD conrol versus HFD IR∆myel) 
 
To further elucidate which insulin target tissues are responsible for the enhanced 
glucose metabolism in diet-induced obese IR∆myel mice, euglycemic-hyperinsulinemic 
clamp analyses were performed. Hepatic glucose production (HGP) was assessed in 
control mice and IR∆myel mice after 12 weeks on HFD. Although no difference was 
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observed in insulin's ability to suppress HGP, the basal i.e. non-suppressed glucose 
production was significantly reduced in livers of obese IR∆myel mice (Fig. 14). 
 
 
Fig. 14: Obese IR∆myel mice exhibit decreased hepatic glucose production. 
Hepatic glucose production (HGP) in 16 week old HFD-fed control mice and IR∆myel mice was determined 
before (basal) and during (steady-state) euglycemic-hyperinsulinemic clamp analysis. (All data are presented 
as mean ± SEM; n = 10 vs 13; *p ≤ 0.05) 
 
Since WAT, skeletal muscle and brain represent major target tissues for insulin-
stimulated carbohydrate uptake, glucose disposal rate was determined in these organs. As 
depicted in Fig. 15, glucose uptake during the clamp was drastically enhanced in skeletal 
muscle of obese IR∆myel mice compared to obese control mice. In contrast, uptake into the 
WAT and brain was, at least under clamp conditions, unaltered between the two 
genotypes. 
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Fig. 15: Obese IR∆myel mice show enhanced insulin-stimulated glucose disposal in skeletal muscle. 
Steady-state insulin-stimulated glucose uptake rate (202) was determined in euglycemic-hyperinsulinemic 
clamp analysis. GUR was measured in WAT, skeletal muscle (SM) and brain of obese control mice and 
IR∆myel mice after 16 weeks of HFD. (All data are presented as mean ± SEM; n = 10 vs 13; *p ≤ 0.05) 
 
Responsiveness of the adipose tissue to the metabolic effects of insulin is crucial for 
maintenance of energy homeostasis. Its role in the development of T2DM, especially in the 
context of immune cell/adipocyte crosstalk, is of central importance to the concept of 
obesity-induced insulin resistance. Therefore, it was mandatory to further investigate 
adipocyte-autonomous insulin signaling in IR∆myel mice. To this end, adipocytes of control 
mice and IR∆myel mice were isolated and stimulated with different doses of insulin in vitro. 
Although no difference in glucose uptake could be observed after stimulation with 1, 10 
and 100 nm insulin adipocytes of IR∆myel mice took up significantly more glucose 
compared to control mice when stimulated with a concentration of 0,1 nm insulin (Fig. 16). 
These data indicate that myeloid cell-restricted insulin receptor deficiency, despite 
enhancing glucose uptake in skeletal muscle, also improves insulin action in adipocytes by 
shifting the dose response curve without altering the maximal response.  
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Fig. 16: Low dose insulin-stimulated glucose uptake is enhanced in adipocytes of obese IR∆myel mice. 
Freshly isolated adipocytes of control mice and IR∆myel mice were stimulated with 0, 0.1, 1, 10 and 100 nm 
insulin in vitro and glucose uptake rate (202) was determined. (All data are presented as mean ± SEM; n = 5 
vs 5; *p ≤ 0.05) 
 
In conclusion, myeloid cell-specific disruption of the insulin receptor protects against 
obesity-induced insulin resistance by reducing basal hepatic glucose production and 
facilitating insulin-stimulated glucose disposal in skeletal muscle and adipose tissue. 
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3.4 The Effect of Myeloid Cell-restricted Insulin Receptor 
Deficiency on Obesity-induced Inflammation 
Obesity is associated with a local and systemic rise in inflammatory markers 
originating from activated immune cells infiltrating the white adipose tissue. This increase 
of cytokines activates pro-inflammatory pathways in insulin target tissues leading to the 
induction of JNK and NFκB signaling which can either directly or indirectly block insulin 
signaling components. To analyze the pro-inflammatory effect of high fat feeding in 
IR∆myel mice, serum cytokine concentrations were determined. As shown in Fig. 17, HFD 
induced an increase in the concentration of circulating TNF-α and reduced that of 
adiponectin in control mice. This response to high fat feeding could not be observed in 
IR∆myel mice. TNF-α concentration in blood serum of obese IR∆myel mice remained 
unchanged compared to lean animals. Similarly, adiponectin concentration was unaltered 
between IR∆myel mice on NCD compared to HFD. 
 
 
Fig. 17: The obesity-associated change of serum TNF-α and adiponectin concentration is abolished in 
IR∆myel mice. 
Serum concentration of TNF-α (a) and adiponectin (b) was measured by ELISA in control mice and IR∆myel 
mice fed either NCD or HFD for 16 weeks. (All data are presented as mean ± SEM; NCD n = 12 vs 13; HFD 
n = 20 vs 20; *p ≤ 0.05) 
 
As previously described, the chronic low-grade inflammatory state encountered in 
obese subjects leads to insulin resistance in insulin target tissues at least partially due to 
increased JNK activity. To directly measure the activation state of this signaling pathway, 
an in vitro assay for the determination of JNK activity was performed. Liver and skeletal 
muscle protein extracts from obese control mice and IR∆myel mice were analyzed and 
significantly lower JNK activity was detected in skeletal muscle of the latter (Fig. 18). This 
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indicates that despite unaltered obesity in IR∆myel mice, the systemic, obesity-associated 
proinflammatory tone is reduced. 
 
 
Fig. 18: Obese IR∆myel mice show reduced JNK activity in skeletal muscle. 
Protein extracts from skeletal muscle (SM) and liver of HFD-fed control mice and IR∆myel mice were 
analyzed for JNK activity. Western blots showing the in vitro phosphorylation of c-jun (a) were 
densitometrically quantified (b). Total JNK levels from the initial lysate (JNK input) were used as a loading 
control. (All data are presented as mean ± SEM; n = 6 vs 6; *p ≤ 0.05) 
 
Local increase of inflammatory cytokine and chemokine expression in adipose tissue 
is a hallmark of obesity. Therefore, mRNA levels of the pro-inflammatory cytokine TNF-
α, the chemokines CCL2 and CCL3 and adiponectin were determined in WAT samples of 
control mice and IR∆myel mice (Fig. 19). As expected, high fat feeding significantly 
increased inflammatory gene expression in WAT of control mice. In contrast, exposure to 
HFD failed to induce TNF-α and CCL3 gene expression in IR∆myel mice to the extent 
observed in the controls. Also, adiponectin mRNA expression was significantly elevated in 
obese IR∆myel mice compared to control mice. CCL2 mRNA levels were slightly decreased 
but the difference did not reach significance. 
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Fig. 19: Obesity-induced change of adipokine gene expression is blunted in IR∆myel mice. 
WAT samples of control mice and IR∆myel mice fed either NCD or HFD were analyzed by quantitative 
realtime PCR. Relative mRNA levels of TNF-α, CCL2, CCL3 and adiponectin were measured in 16 week 
old mice. Hprt1 mRNA was used as endogenous control. (All data are presented as mean ± SEM; n = 8 vs 8; 
*p ≤ 0.05) 
 
In conclusion, myeloid cell-autonomous insulin resistance diminishes the typical, 
obesity-associated rise in circulating inflammatory markers and activation of inflammatory 
protein kinase JNK in peripheral organs. Furthermore, a local and systemic increase in 
adiponectin mRNA and protein levels, respectively, was observed.  
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3.5 The Effect of Myeloid Cell-restricted Insulin Receptor 
Deficiency on Adipose Tissue Inflammation and 
Macrophage Accumulation 
Since macrophages have been shown to contribute significantly to the enhanced 
inflammatory profile of the expanding adipose tissue under obesity, gene expression of a 
macrophage-specific marker (F4/80) was determined in this tissue. As expected, obesity 
led to a substantial increase in F4/80 mRNA expression (Fig. 20a) in white adipose tissue 
of diet-induced obese control mice compared to lean animals. However, while lean mice 
from both genotypes showed the same expression level of F4/80 mRNA, the obesity-
induced increase of this marker was sigificantly blunted in HFD-fed IR∆myel mice. 
Nevertheless, the cell-autonomous expression of F4/80 was unchanged between bone 
marrow-derived macrophages of both genotypes, neither at the basal level nor after 
stimulation with palmitic acid (Fig. 20b). 
 
 
 
 
Fig. 20: Reduced macrophage surface marker expression in adipose tissue of obese IR∆myel mice. 
F4/80 mRNA expression was assessed by quantitative realtime PCR analysis in (a) WAT of NCD and HFD 
fed control mice and IR∆myel mice and (b) untreated (basal) or palmitic acid (P, 500 µM) stimulated bone 
marrow-derived macrophages from control mice and IR∆myel mice. Hprt1 mRNA was used as endogenous 
control (All data are presented as mean ± SEM; WAT n = 5 vs 5; BMDM n = 4 vs 4; *p ≤ 0.05) 
 
Moreover, white adipose tissue was analyzed microscopically for changes in 
morphology. As depicted in Fig. 21, when stained with hematoxylin and eosin (H&E) 
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adipose tissue morphology was indistinguishable between obese control mice and IR∆myel 
mice. 
 
 
 
Fig. 21: Adipose tissue morphology of IR∆myel mice and control mice exposed to HFD. 
H&E staining of paraffin sections from WAT of 16 week old obese control mice and IR∆myel mice. 
(Magnification: 100-fold) 
 
Additionally, adipocyte size was analyzed in white adipose tissue sections of HFD-
fed control mice and IR∆myel mice. As shown in Fig. 22a, the mean cell size reached 
approximately 10000 µm² in both genotypes. In addition, adipocyte size occurence curves 
displayed Gauss distribution without revealing any significant difference between the 
genotypes investigated (Fig. 22b). 
 
 
Fig. 22: Quantification of adipocyte size and size distribution. 
Mean adipocyte size (a) and cell size distribution (b) in WAT was quantified in adipose tissue sections from 
control mice and IR∆myel mice. (All data are presented as mean ± SEM; n = 9 vs 9) 
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Upon weight gain, macrophages infiltrate the expanding adipose tissue and form 
crown-like structures (CLS) arround dead adipocytes for removal of cell debris and tissue 
remodeling. Mac-2, a 30-35 kDa galactose-binding protein, is specifically expressed on the 
surface of macrophages upon activation (203). In order to detect activated macrophages in 
adipose tissue, immunohistochemical analysis with an antibody directed against Mac-2 
was performed. In line with the observed reduction of macrophage marker mRNA 
expression, microscopical analysis revealed a dramatically reduced number of CLS in 
adipose tissue sections of obese IR∆myel mice compared to control mice (Fig. 23, upper 
panel). Likewise, quantification of total CLS area per section revealed a significant 
reduction in IR∆myel mice (Fig. 23, lower panel). 
 
 
 
Fig. 23: Obese adipose tissue of IR∆myel mice shows decreased formation of crown-like structures. 
Paraffin sections from WAT of 16 week old obese control mice and IR∆myel mice were 
immunohistochemically stained with Mac-2 antibody (upper panel, magnification 100-fold) and the area of 
Mac-2 positive crown-like structures (CLS) was quantified (lower panel). Red arrows indicate CLS. (All data 
are presented as mean ± SEM; n = 9 vs 9; *p ≤ 0.05)  
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The adipose tissue consists of two main fractions, adipocytes and stromal vascular 
cells. To precisely attribute the previously observed reduction of TNF-α mRNA expression 
to one of these compartments, white adipose tissue of obese control mice and IR∆myel mice 
was separated into these two fractions. Quantitative realtime PCR analysis of leptin 
mRNA, which is exclusively expressed in adipocytes, was taken as a quality control for the 
separation process. Stromal vascular cells expressed approximately 90% less leptin mRNA 
compared to adipocytes (Fig. 24). Expression levels of macrophage surface markers F4/80, 
Mac-2 and CD11c mRNA were 2-fold to 4-fold increased in stromal vascular cells of 
control mice compared to adipocytes. Concomitant with reduced CLS formation (Fig. 23), 
expression of Mac-2 as well as F4/80 mRNA was significantly reduced in the stromal 
vascular fraction of IR∆myel mice compared to control mice. However, CD11c expression 
was unchanged between IR∆myel mice and control mice. Furthermore, TNF-α mRNA 
expression was 5-fold elevated in stromal vascular cells compared to adipocytes isolated 
from control mice. Nevertheless, the stromal vascular cells of IR∆myel mice expressed 
significantly lower TNF-α mRNA than those of control mice (Fig. 24).  
 
 
 
Fig. 24: Reduced TNF-α expression in adipose tissue-derived stromal vascular cells of IR∆myel mice.  
WAT of control mice and IR∆myel mice was seperated into adipocytes (Adi) and stromal vascular cells (167). 
Relative mRNA expression of F4/80, Mac-2, CD11c and TNF-α was determined by quantitative realtime 
PCR. To estimate fractionation efficiency, Leptin mRNA expression was determined in both fractions. Hprt1 
mRNA was used as endogenous control. (All data are presented as mean ± SEM; n = 6 vs 5; *p ≤ 0.05; **p ≤ 
0.01; ***p ≤ 0.001) 
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Taken together, these data demonstrate that myeloid cell-restricted insulin resistance 
reduces the inflammatory infiltration of adipose tissue by macrophages, which is generally 
associated with high fat feeding and obesity. This blunted macrophage accumulation in 
turn leads to reduced expression of TNF-α mRNA in the stromal vascular compartment of 
the obese adipose tissue of IR∆myel mice. 
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3.6 Cell-Autonomous Effects of Insulin Receptor Deficiency on 
Macrophages 
The reason for the observed reduction of adipose tissue macrophage content and 
inflammatory gene expression in obese IR∆myel mice could arise from (I) enhanced 
susceptibility to apoptosis, (II) impaired inflammatory response of insulin receptor-
deficient macrophages or (III) reduced invasive capacity of these cells.  
 
 
3.6.1 The Effect of Insulin on Macrophage Apoptosis 
To investigate the first hypothesis, bone marrow-derived macrophages from control 
and IR∆myel mice were stimulated with insulin, palmitic acid or both and the number of 
apoptotic cells was analyzed for DNA fragmentation by TUNEL assay. As depicted in Fig. 
25, approximately 10% of control and IR-/- macrophages showed DNA fragmentation 
under basal conditions. Strikingly, exposure to insulin significantly reduced the number of 
TUNEL positive cells in control but not in IR-deficient macrophages. Furthermore, 
stimulation with palmitic acid drastically enhanced apoptosis in control and IR-deficient 
macrophages to approximately 45%. Moreover, costimulation with insulin significantly 
reduced the number of apoptotic control macrophages by 10%. This anti-apoptotic effect 
of insulin could not be observed in IR-/- macrophages.  
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Fig. 25: Enhanced apoptosis in insulin receptor-deficient macrophages. 
Bone marrow-derived macrophages were stimulated with insulin (50 ng/ml), palmitic acid (P, 500 µM) or 
both for 24 h in serum-free medium and the number of TUNEL-positive (155) cells was determined. DAPI 
staining of nuclei (blue) was performed for total cell number. (Fluorescence microscopy: upper panel; 
quantification: lower panel; All data are presented as mean ± SEM; n = 4 vs 4; *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 
0.001) 
 
To further investigate the enhanced palmitic acid-induced apoptosis in insulin 
receptor-deficient macrophages, quantitative realtime PCR analysis of pro- and anti-
apoptotic gene expression was performed. Stimulation with palmitic acid induced a 3-fold 
increase in mRNA expression of Bcl2-associated X protein (Bax) after 8 h compared to the 
basal level. However, stimulation with insulin did not alter Bax mRNA levels. Also, no 
difference could be observed between control and IR-deficient macrophages under any 
condition analyzed (Fig. 26a).  
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In contrast, Bcl-2 mRNA expression was strongly reduced after exposure of bone 
marrow-derived macrophages to palmititc acid compared to the basal level (Fig. 26b). The 
addition of insulin significantly increased the expression of Bcl-2 in control macrophages. 
However, this effect was not observed in IR-deficient macrophages. Under the influence of 
palmitic acid, insulin also induced an increase in Bcl-2 expression of control cells. 
Nevertheless, this induction was not significant after 8 h of stimulation.  
 
 
Fig. 26: Insulin enhances expression of Bcl-2 mRNA in bone marrow-derived macrophages. 
Bone marrow-derived macrophages from control (white columns) or IR∆myel mice (black columns) were 
stimulated with insulin (Ins, 50 ng/ml), palmitic acid (P, 500 µM) or both for 8 h in serum-free medium and 
expression of  (a) Bax, (b) Bcl-2, (c) XBP-1 and (d) Chop mRNA was analysed by quantitative realtime 
PCR. Hprt1 and Gusb mRNA were used as endogenous controls. (All data are presented as mean ± SEM; n = 
4 vs 4; *p ≤ 0.05; ***p ≤ 0.001) 
 
In addition, the expression of ER stress-induced genes was determined in control and 
IR-deficient macrophages. Stimulation with palmitic acid significantly induced the 
expression of XBP-1 and Chop mRNA while no difference could be observed between 
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genotypes (Fig. 26c, d). Although insulin displayed no significant effect on the expression 
of the two genes, macrophages of IR∆myel mice exhibited a tendency towards reduced XBP-
1 expression after exposure to palmitic acid and reduced Chop expression after combined 
insulin and palmitic acid stimulation, when compared to control cells. 
 
 
3.6.2 The Effect of Insulin on Pro-inflammatory Gene Expression 
To investigate the second hypothesis, namely that insulin regulates pro-
inflammatory gene expression, bone marrow-derived macrophages from control and 
IR∆myel mice were again stimulated with insulin, palmitic acid or both. Induction of pro-
inflammatory gene expression was analyzed by quantitative realtime PCR after a 
stimulation period of 8 h. While mRNA levels of TNF-α and IL-6 were unchanged in non-
stimulated cells, exposure to insulin increased the expression of both genes 2-fold in 
control macrophages. However, insulin failed to enhance TNF-α and IL-6 gene expression 
in macrophages derived from bone marrow of IR∆myel mice (Fig. 27a). After stimulation 
with palmitic acid, macrophages of both genotypes displayed a marked increase of TNF-α 
and IL-6 mRNA expression compared to untreated cells (Fig. 27b). Furthermore, a 
combination of palmitic acid and insulin slightly increased the expression of TNF-α in 
control macrophages. In contrast, palmitic acid-induced IL-6 mRNA expression was 
slightly reduced by insulin in these cells. However, neither the insulin-induced increase of 
TNF-alpha nor the decrease of IL-6 mRNA levels under lipid load could be observed in 
macrophages derived from IR∆myel mice. 
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Fig. 27: Insulin augments pro-inflammatory gene expression in macrophages. 
Bone marrow-derived macrophages from control mice (white columns) or IR∆myel mice (black columns) were 
stimulated with (a) insulin (Ins, 50 ng/ml), (b) palmitic acid (P, 500 µM) or both for 8 h and expression of 
TNF-α and IL-6 mRNA was analyzed by quantitative realtime PCR. Hprt1 and Gusb mRNA was used as 
endogenous control. (All data are presented as mean ± SEM; n = 4 vs 4; **p ≤ 0.01) 
 
To directly assess pro-inflammatory cytokine production in control and insulin 
receptor-deficient macrophages, TNF-α and IL-6 ELISA was performed with supernatants 
of these cells. As depicted in Fig. 28a, macrophages of control mice released significantly 
more TNF-α protein in response to insulin in the absence of other stimuli. Also, in 
macrophages of IR∆myel mice, stimulation with insulin tended to result in enhanced TNF-α 
production but this increase was not significant. Upon stimulation with palmitic acid, TNF-
α release was further increased compared to insulin. However, no difference was observed 
between genotypes or after costimulation with palmitic acid and insulin. The release of IL-
6 was not affected in macrophages of IR∆myel mice compared to controls under any 
condition analysed (Fig. 28b). 
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Fig. 28: Insulin enhances secretion of TNF-α in macrophages. 
Bone marrow-derived macrophages of control and IR∆myel mice were stimulated with insulin (Ins, 50 ng/ml), 
palmitic acid (P, 500 µM) or both for 24 h in serum-free medium and secretion of (a) TNF-α and (b) IL-6 
was determined by ELISA. (All data are presented as mean ± SEM; n = 4 vs 4; **p ≤ 0.01) 
 
 
3.6.3 The Effect of Insulin on Macrophage Migration 
An important factor for macrophage migration is their ability to express and secrete 
matrix metalloproteinases (MMPs) which then help to degrade extracellular matrix (ECM) 
proteins to allow trans-ECM migration. It has recently been demonstrated that insulin 
regulates the activity of MMP-9, a member of the type IV collagenase subgroup, in a 
human monocytic cell line. To investigate the effect of insulin on MMPs in our model, 
peritoneal macrophages from control and IR∆myel mice were analyzed for expression of 
MMP-9 mRNA after stimulation with palmitic acid in the presence of serum. As shown in 
Fig. 29a, MMP-9 mRNA levels were already significantly reduced in untreated 
macrophages of IR∆myel mice compared to controls. This difference was even more 
pronounced after stimulation with palmitic acid where MMP-9 mRNA was increased 2.5-
fold in control macrophages while insulin receptor-deficient macrophages could enhance 
MMP-9 expession only 0.5-fold. To directly test the effect of insulin on MMP-9 activity in 
primary murine macrophages, gelatinase zymography was performed. Stimulation of bone 
marrow-derived macrophages of control mice with insulin induced MMP-9 activity in the 
cell culture supernatant (Fig. 29). However, this insulin-mediated increase of MMP-9 
gelatinolytic activity could not be observed in supernatant of IR-deficient macrophages. 
 
   Results 
 
-57- 
  
 
Fig. 29: Insulin receptor deficiency impairs matrix metalloproteinase 9 expression in macrophages. 
(a) Peritoneal macrophages of control (white columns) and IR∆ymel mice (black columns) were treated with 
palmitic acid or left untreated (basal) for 4 h and expression of MMP-9 mRNA was analysed by quantitative 
realtime PCR. Hprt1 was used as endogenous control. (b)  Cell culture supernatants from 24 h untreated 
(basal) or insulin-stimulated (50 µg/ml) bone marrow-derived macrophages of control and IR∆myel mice (IR-/-) 
were analyzed by gelatinase zymography. A representative zymogram of three independent experiments is 
shown (M = protein marker lane; pro-MMP-9 protein size = 105 kDa; All data are presented as mean ± SEM; 
**p ≤ 0.01) 
 
Boyden chamber analysis, where two compartments are separated by a porous 
membrane, provides a proper tool for accurate determination of chemotactic behaviour 
(204). Motile cells are placed into the upper compartment, while the test substance-
containing fluid is filled into the lower one. To directly address the migratory potential of 
insulin receptor-deficient macrophages, Boyden chamber experiments were employed. As 
depicted in Fig. 30, non-directed (basal) chemotaxis was indistinguishable between control 
and insulin receptor-deficient macrophages. However, when directed against 25 and 6 
ng/ml of the potent chemoattractant MCP-1, control cells showed increased migration 
towards the lower compartment. Chemotaxis was not induced with 1.5 ng/ml of MCP-1. 
Strikingly, insulin receptor-deficient macrophages did not increase their migration activity 
when exposed to MCP-1. 
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Fig. 30: Insulin receptor-deficient macrophages show impaired chemotactic abbilities. 
Bone marrow-derived macrophages of control and IR∆myel mice were tested for their chemotactic abilities. 
Chemotaxis against buffer (basal) and different concentrations of MCP-1 was determined. (All data are 
presented as mean ± SEM; n = 3 vs 3; ** p ≤ 0.01) 
 
These data indicate that insulin mediates potent effects on three macrophage key 
functions. Firstly, it was demonstrated that the hormone promotes macrophage survival 
under the cytotoxic influence of palmitic acid and enhances expression of Bcl-2. Secondly, 
insulin was able to increase basal transcription of TNF-α and IL-6 whereas a combination 
of insulin and palmitic acid augmented the expression of TNF-α while it reduced 
expression of IL-6. However, secretion of TNF-α and IL-6 by macrophages of IR∆ymel mice 
was not affected although insulin could significantly increase TNF-α release in control 
macrophages. Finally, insulin was able to enhance expression and secretion of active 
MMP-9 by control but not IR-deficient macrophages. Additionally, the chemotactic ability 
of insulin receptor-deficient macrophages towards MCP-1, as assessed by Boyden chamber 
analysis, was drastically impaired.Taken together, macrophage-autonomous insulin action 
provides an important signal in controlling metabolic disturbances associated with obesity. 
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4 Discussion 
Over the past several years the interplay between inflammatory pathways and insulin 
action has attracted increasing interest. Interference with certain cytokine-induced 
signaling pathways and a reduction in obesity-induced inflammation have been 
demonstrated to provide a potential avenue in the treatment of systemic insulin resistance 
and impaired glucose metabolism (113, 115). Although the relative contribution and the 
interaction of cytokine-stimulated JNK and NFκB activation has not been fully elucidated 
and may exhibit differential, tissue-specific effects, it is evident that inhibiting cytokine-
evoked NFκB activation in myeloid cells prevents obesity-associated insulin resistance 
(114, 115, 205). However, little attention has been given to the effects of insulin itself on 
macrophage function particularly in the context of the obesity-induced pro-inflammatory 
state. 
In this study, conditional disruption of the insulin receptor was employed to analyze 
the effect of myeloid cell-autonomous insulin resistance on the development of obesity-
induced insulin resistance.  
 
 
4.1 Recombination Efficiency of the LysMCre Transgene 
Inactivation of insulin receptor signaling has been achieved through use of the Cre-
loxP system. The site-specific DNA recombinase Cre (causes recombination) is a 38 kDa 
protein of the bacteriophage P1 that recognizes specific 34 bp palindromic sequences, 
termed loxP (locus of crossing (x) over in P1) sites (206). Depending on the orientation of 
the loxP sites the Cre recombinase mediates the inversion, excision or translocation of the 
DNA sequence that is flanked by the two loxP sequences (207). DNA sequences flanked 
by directly repeating loxP sites are excised as a circular molecule, leaving a single loxP 
sequence at the site of recombination (208). Cre-transgenic mouse strains are generated 
either by conventional random transgenics, targeted insertion into a gene (knock-in) or by 
generating bacterial artificial chromosome (BAC)-transgenic mice (209, 210). Regardless 
of the strategy, the promotor which drives Cre expression determines onset and cell type-
specificity of the Cre-mediated recombination. By crossing mice carrying a loxP-flanked 
mutation of the gene of interest with mice expressing the Cre recombinase restricted to 
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specific tissues, a conditional mouse mutant is generated that lacks the target gene only in 
cells in which Cre is expressed. 
Expression of the Cre recombinase under control of the lysozyme M promotor 
(LysMCre) has already successfully been used in numerous studies to conditionally delete 
loxP-flanked genome regions specifically in myeloid cells (114, 211). Hence, this 
approach was used in the current study to disrupt the insulin receptor allele in these cells. 
Ablation efficiency was verified in peritoneal and bone marrow-derived macrophages on 
genomic DNA, mRNA and protein level. The residual 10% of loxP-flanked alleles 
detected in bone marrow-derived macrophages of IR∆myel mice can be attributed to 
contamination with either immune cells of the lymphoid lineage or fibroblasts from the 
isolation process. Also, the mice generated in this study are heterozygous for the LysMCre 
allele which could reduce the full Cre-mediated recombination potential (201). 
Transcription of the insulin receptor mRNA in bone marrow-derived macrophages was 
also not completely abolished as demonstrated by quantitative realtime PCR. These cells 
still expressed 15% of insulin receptor mRNA detected in control macrophages. However, 
western blot analysis of protein lysates from peritoneal macrophages demonstated a 
complete absence of immunodetectable insulin receptor protein in cells derived from 
IR∆myel mice. The discrepancy observed in DNA/mRNA versus protein expression can 
attributed to two reasons. Firstly, southern blot analysis and quantitative realtime PCR 
provide more sensitive detection methods compared to western blot analysis. Secondly, in 
vitro differentiation of macrophages from bone marrow results in a homogenous 
population of resting macrophages whereas the thiogycolate-elicited peritoneal cell 
population is heterogenous, consisting mainly of inflammatory, activated macrophages. 
Since lysozyme is strongly induced in activated macrophages (212), it seems likely that 
lysozyme M promotor-driven Cre expression is also enhanced in these cells and thus 
deletion efficiency is increased. Given that obesity results in recruitment of activated 
macrophages to adipose tissue - although not directly addressed in the present study - it 
appears very likely that deletion efficiency in these cells is also high. The analysis of 
insulin receptor protein expression in various tissues of IR∆myel mice revealed no difference 
compared to control mice although resident macrophages can be found in almost all tissues 
throughout the body. Isolation and purification of these macrophage populations and 
subsequent analysis by southern blot or quantitative realtime PCR would provide a 
superior approach to further investigate the recombination efficiency in tissue resident 
macrophages. 
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However, here it has been shown that the LysMCre transgene provides an adequate 
tool to mediate specific and efficient disruption of the insulin receptor in resting and 
inflammatory macrophages. 
 
 
4.2 Myeloid Cell-specific Disruption of the Insulin Receptor 
protects against Obesity-induced Insulin Resistance 
In this study, the commonly employed model of high fat feeding was used to analyze 
the effect of myeloid cell-restricted insulin resistance on obesity-induced insulin resistance. 
In control animals, the exposure to a high fat diet (55.2% calories from fat) lead to severe 
obesity accompanied by a marked increase in circulating leptin, insulin and glucose 
concentrations compared to lean animals. Moreover, control mice exhibited a pronounced 
impairment of glucose metabolism and insulin action indicated by increased blood glucose 
levels and reduced responsiveness to insulin during glucose tolerance test and insulin 
tolerance test, respectively. Myeloid cell-restricted insulin receptor deficiency did not 
affect obesity. This was not entirely surprising since myeloid cell-specific disruption of 
genes that are fundamentally involved in the regulation of macrophage function e.g. IKKβ 
and JNK1, either by using the Cre-loxP system or bone marrow transplantation techniques, 
did not modulate adiposity (114, 158). Until now, changes in body weight after myeloid 
cell-specific gene deletion were reported only once (168). In this study, transplantion of 
PPARγ-deficient bone marrow cells into lethally irradiated wildtype mice lead to increased 
weight gain upon high fat feeding.  
However, although adiposity was unchanged, IR∆myel mice showed a striking 
protection from obesity-induced hyperglycemia and hyperinsulinemia, two parameters 
commonly used to define insulin resistance. Furthermore, these mice performed 
considerably better in glucose and insulin tolerance tests. As demonstrated by euglycemic-
hyperinsulinemic clamp analysis, this arises from enhanced insulin-stimulated glucose 
uptake into skeletal muscle and reduced basal hepatic glucose production. Although 
glucose uptake into adipose tissue was unaltered during clamp conditions, isolated 
adipocytes of obese IR∆myel animals displayed enhanced insulin-stimulated glucose uptake 
in vitro. These cells showed higher sensitivity to insulin, reflected by a shift of the dose 
response curve without altering the maximal response. Notably, glucose uptake into 
adipocytes of IR∆myel mice was markedly increased in response to low rather than high 
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doses insulin. These experiments explain why glucose uptake was unaltered in adipose 
tissue of IR∆myel mice during clamp conditions, an experimental setup in which high 
concentrations of insulin are applied. These data clearly demonstrate that myeloid cell-
autonomous insulin resistance protects against the deleterious effect of obesity on glucose 
metabolism in main insulin target tissues. This is consistent with previous observations that 
mice with hepatic inactivation of IKKβ retained insulin responsivness in the liver whereas 
myeloid cell-restricted disruption of IKKβ resulted in protection against obesity-induced 
insulin resistance in liver, skeletal muscle and adipose tissue (114). Together with the 
results of the current study, these findings underline the crucial role of myeloid cells in the 
control of systemic insulin action under obesity. 
 
 
4.3 Myeloid Cell-specific Disruption of the Insulin Receptor 
modulates the Obesity-associated Pro-inflammatory Tone 
Aside from improved glucose metabolism and insulin sensitivity, obese IR∆myel mice 
showed decreased concentration of TNF-α and increased concentration of adiponectin in 
the circulation when compared to control mice. Circulating TNF-α activates pro-
inflammatory kinases like JNK in insulin target tissues leading to S307 phosphorylation of 
IRS molecules thereby inhibiting insulin action (113). In contrast, adiponectin has been 
shown to improve glucose metabolism through activation of adenosine monophosphate-
activated kinase (AMPK) and inhibition of hepatic gluconeogenesis (213). The observed 
alteration in concentation of these two proteins may benefit and augment insulin sensitivity 
in IR∆myel mice upon obesity.  
In line with reduced circulating TNF-α, the analysis of JNK in skeletal muscle 
revealed a dramatic reduction of kinase activity in this tissue. This could potentially 
explain the enhanced glucose disposal i.e. insulin sensitivity of skeletal muscle, since 
increased local JNK activity was demonstrated to be positively correlated with muscle 
insulin resistance (214). However, the question remains why JNK activity in the liver of 
IR∆myel mice is only slightly decreased although hepatic glucose production is reduced in 
this tissue. A possible explanation could be that immune cells residing in the liver, 
maintain local pro-inflammatory signaling (169). Notably, hepatic glucose production is 
reduced only in the fasted state while remaining unaltered between control and IR∆myel 
animals after stimulation with insulin. Hence, one could speculate that increased inhibition 
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of hepatic glucose production i.e. gluconeogenesis in obese IR∆myel mice is a result of the 
action of adiponectin rather than enhanced hepatic insulin sensitivity. Assessment of 
AMPK activity, as well as expression of gluconeogenic genes and inflammatory mediators 
in liver of IR∆myel mice should help to further define the exact cause of decreased basal 
hepatic glucose production. Moreover, adiponectin has been shown to form higher-order 
complexes that are differentially distributed in lean, obese and insulin resistant subjects 
(215). Therefore, determining the abundancy of different adiponectin complexes in the 
circulation of obese IR∆myel mice would be of interest to analyze. 
 
 
4.4 Myeloid Cell-specific Disruption of the Insulin Receptor 
blunts the Inflammatory Infiltration of Adipose Tissue by 
Macrophages 
In the past several years, the inflammatory infiltration of adipose tissue by 
macrophages and a subsequent increase of pro-inflammatory gene expression has become 
a central paradigm in obesity-induced insulin resistance (156, 157). Taking the augmented 
glucose metabolism of IR∆myel mice into consideration, analysis of adipose tissue 
inflammation and macrophages infiltration represented an interesting approach to further 
characterize these mice. Diet-induced obese IR∆myel mice showed a dramatic reduction of 
pro-inflammatory gene expression in adipose tissue indicated by reduced TNF-α mRNA 
levels. Increased TNF-alpha expression in adipose tissue has been demonstrated to be an 
important feature of obesity and insulin resistance in humans and rodents (104, 105). 
Furthermore, neutralization of TNF-alpha in rodents caused a significant increase in 
peripheral glucose metabolism and insulin action (104). This suggests that the reduction in 
TNF-α alone, both locally and systemically, reduces the systemic inflammatory tone, 
thereby exerting a beneficial effect on glucose metabolism and insulin sensitivity in IR∆myel 
mice.  
A considerable amount of TNF-α is expressed by adipocytes. In obesity, however, 
macrophages are the predominant source of this cytokine (156). Accordingly, we could 
show that the observed reduction of TNF-α mRNA expression in IR∆myel mice is 
attributable solely to a reduction in the stromal vascular compartment of the adipose tissue, 
which is the site of macrophage accumulation, while expression was unchanged in 
adipocytes. Along with diminished TNF-α expression we observed a striking reduction of 
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macrophage markers, both on mRNA (F4/80, Mac-2) and protein level (Mac-2). However, 
expression of CD11c, a surface marker which has recently been shown to be specific for 
pro-inflammatory M1 macrophages (165), was unchanged in stromal vascular cells of 
IR∆myel mice. Nonetheless, since CD11c is known to be expressed not only by 
macrophages but also by dendritic cells (216), the mRNA expression determined in our 
model could be derived predominantly from these cells, potentially masking any 
alterations specifically in macrophages.  
Chemokines are potent endogenous chemoattractants for macrophages and 
monocytes. Increased expression of CCL2 (protein: MCP-1) has been associated with 
obesity and insulin resistance and its production is enhanced during euglycemic 
hyperinsulinemia in insulin resistant patients (119, 217, 218). It has been postulated that 
adipose tissue derived MCP-1 contributes to increased macrophage infiltration in obesity 
(160). In this study, adipose tissue expression of CCL2 was increased by 300% upon high 
fat feeding. However, with an increase of 2500% in control animals, CCL3 (protein: MIP-
1α) was induced unequally stronger than CCL2. Furthermore, the increase of CCL3 but not 
of CCL2 gene expression was significantly abolished in white adipose tissue of obese 
IR∆myel mice. This indicates that in our model, local changes in CCL3 rather than CCL2 
expression are responsible for the reduced infiltration of adipose tissue by macrophages. 
So far, the increase of MCP-1 but not MIP-1α serum concentration has been associated 
with obesity (119). Interestingly, it has been shown that the adipose tissue does not 
contribute to this systemic increase and adipose tissue-derived MCP-1 only acts in a 
paracrine fashion (219). Additionally, obese subjects exhibit significantly elevated serum 
but not adipose tissue-interstitial MCP-1 concentrations, when compared to lean subjects 
(220). Taken this into account, an intriguing question left to address would be whether 
local and systemic MCP-1 and MIP-1α are differentially regulated in IR∆myel mice. 
Taken together, the protection from obesity-associated insulin resistance due to 
impaired insulin action in myeloid cells occurs on two levels. The obesity-induced 
inflammatory infiltration of macrophages into white adipose tissue is dramatically reduced 
in IR∆myel mice. This results in reduced local expression and presumably release of TNF-α 
into the bloodstream, subsequently blunting the obesity-associated rise in circulating 
inflammatory markers. As a result, the systemic and chronic low-grade inflammation 
typically found in obese individuals is abrogated (221), thereby preventing the occurrence 
of obesity-induced insulin resistance. 
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4.5 The Effect of Metabolic Stress on Macrophages 
In this study, we sought to expose primary murine macrophages to stimuli which are 
adequately comparable to the environment encountered in obesity. Special interest was 
given to hyperlipidemia, here represented by the long chain saturated fatty acid palmitate, 
as lipids have been demonstrated to exhibit strong modulatory effects on macrophage 
function (132, 158, 222, 223). The applied amount of palmitic acid (500 µM) is 
comparable to physiological concentrations of fatty acids observed in obese humans and 
rodents (224, 225). Also, the applied glucose concentration of 200 mg/dl simulates 
hyperglycemic conditions adequately (226). In the present study, we demonstrate that a 
cell-autonomous insulin receptor deficiency affects macrophages in terms of survival 
under metabolic stress conditions, inflammatory gene expression and chemotaxis. 
 
 
4.5.1 Insulin as a Survival Signal for Macrophages 
By subjecting primary murine macrophages to the various metabolic stimuli 
previously mentioned, it became evident that macrophage survival upon fatty acid load is 
highly dependent on insulin signaling. Insulin efficiently inhibited palmitic acid-induced 
apoptosis in control macrophages as assessed by DNA fragmentation (TUNEL) assay. 
Furthermore, basal apoptosis was significantly blocked after exposure to insulin. As 
expected, the beneficial effect of insulin on macrophage survival was abolished in 
macrophages from IR∆myel mice. In line with increasing DNA fragmentation, palmitic acid 
significantly reduced the expression of anti-apoptotic Bcl-2 and increased that of pro-
apoptotic Bax. Treatment with insulin significantly enhanced Bcl-2 expression in control 
macrophages under basal conditions while after palmitic acid load, only a tendency 
towards elevated expression of this gene was observed. Taken together, these data suggest 
that the pro-survival effect of insulin is dependent rather on enhanced anti-apoptotic than 
reduced pro-apoptotic gene expression.  
Additionally, a trend towards higher UPR-related gene expression, represented here 
by XBP-1 and Chop, was observed in control macrophages. These results are in line with 
previous observations that insulin, as an inducer of global protein synthesis, increases ER 
stress, thereby activating several members of the UPR (e.g. GRP78, XBP-1) ultimately 
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protecting against cell death (185). In the study by Misra et al., the observed anti-apoptotic 
effect of insulin was mediated by enhanced expression of Bcl-2 and 
phosphorylation/inhibition of forkhead transcription factor family member FOXO1. 
Recently, the relevance of these findings has been underlined further by Senokuchi et al. 
(227), who found that insulin receptor-deficient macrophages exhibited increased 
susceptibility to cholesterol-induced cell death. The cells could be rescued from apoptosis 
by either adenoviral introduction of a constitutively active Akt or genetic disruption of 
FOXO1, thereby restoring the insulin/PI3K-dependent signaling pathways. Notably, in 
contrast to the design of our study, all experiments were performed in the presence of 
serum, raising the question whether the effects observed are genuinely insulin-dependent 
or mediated by the interplay of insulin with other serum-derived factors. Thus, our study 
demonstrates for the first time that insulin alone can promote macrophage survival in a 
lipocytotoxic environment, which is potentially dependent on enhanced anti-apoptotic gene 
expression.  
However, the balance between pro- and anti-apoptotic Bcl-2 protein family 
members localized to the mitochondrial outer membrane plays a central role in the control 
of apoptosis. Pro-apoptotic proteins such as Bax and Bak, either directly or indirectly, 
induce the release of proteins from the space between the inner and outer mitochondrial 
membranes (228, 229). This process of mitochondrial outer membrane permeabilization 
(MOMP) is likely to be achieved by formation of membrane-spanning pores through 
which cytochrome c and other soluble proteins are released into the cytosol (230, 231). 
Anti-apoptotic proteins such as Bcl-2 and Bcl-xL prevent this release, presumably by 
blocking pore formation (232). Furthermore, metabolic processing of saturated fatty acids 
leads to generation of reactive intermediates i.e. reactive oxygen species (ROS). Apoptosis 
induced by these intermediates is characterized by activation of caspases and DNA-
laddering (233). Therefore, analysis of ROS accumulation, caspase activation and cellular 
localization of Bcl-2 family members would yield further insights into the exact 
mechanisms underlying insulin's anti-apoptotic effects in macrophages. 
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4.5.2 Pro-inflammatory Effects of Insulin in Macrophages 
In the current study, we demonstrate that insulin has potent effects on inflammatory 
gene expression in primary murine macrophages. We could show that stimulation with 
insulin enhances transcription of TNF-α and IL-6 in bone marrow macrophages derived 
from control mice while this effect was abolished in macrophages from IR∆myel mice. 
Furthermore, exposure to palmitic acid drastically exacerbated pro-inflammatory gene 
expression. Costimulation with palmitic acid and insulin slightly but significantly 
increased the expression of TNF-α in control macrophages compared to insulin receptor-
deficient cells. Conversely, under lipid load, insulin exerted inhibitory effects on IL-6 gene 
expression in control macrophages. In contrast to its transcriptional effect, insulin could 
not modulate the secretion of TNF-α and IL-6 under lipid load. However, in the absence of 
any other stimuli, exposure to insulin induced a significant increase of TNF-α but not IL-6 
production in control macrophages. These variable effects of insulin in combination with 
other pro-inflammatory stimuli on macrophages have been reported previously and seem to 
be transient. For example, pretreatment with LPS followed by exposure to insulin lead to 
increased release of TNF-α in a human macrophages cell line (234). On the contrary, when 
macrophages were primed with insulin followed by subsequent treatment with LPS, 
activation of NFκB signaling was significantly reduced (235).  However, it was previously 
described that insulin directly induces transcription and release of TNF-α in THP-1 
monocytes (182). In terms of mRNA expression, this could be confirmed in murine 
macrophages and further extended to conditions of hyperlipidemia by the present study. 
Unexpectedly, this pro-inflammatory effect was only partially conveyed to secretional 
level. Interestingly, it was recently demonstrated by Iwasaki et al. that insulin exerts short 
term anti-inflammatory but long term pro-inflammatory effects in hepatocytes (236). In 
this study, a combined TNF-α and insulin treatment resulted in reduced NFκB-dependent 
transcription after 6 h but lead to a drastic enhancement after 36-72 h. This long-term 
effect is in line with previous results obtained in our group, where insulin receptor-
deficient macrophages, when compared to control cells, secreted significantly less IL-6 
after a 72 h stimulation period with LPS (187). Furthermore, compared to a short-term 
response, prolongued exposure to insulin and pro-inflammatory stimuli far better matches 
the conditions encountered in obesity. 
A considerable number of inflammatory genes are expressed through activation of 
NFkB signaling pathways. It has been reported that phosphorylation and proteasomal 
degradation of inhibitors of NFkB (IκB) is dependent on the activity of Akt/protein kinase 
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B and that insulin receptor-deficient macrophages exhibit increased IκBε protein levels 
(227, 237). Although Akt is classically involved in processes like survival, proliferation, 
metabolism and glucose uptake especially in the context of insulin signaling, it may also 
contribute to inflammatory response pathways. Hence, it is plausible that insulin modulates 
pro-inflammatory signaling events throught the PI3K/Akt axis. Additionally, the 
expression of IL-6 in macrophages is mostly regulated through activation of 
CCAAT/enhancer binding protein (C/EBP) β also known as nuclear factor IL-6 (NF-IL6) 
(238). C/EBPβ is differentially regulated through several cellular kinases including PKC, 
PKA, Akt and GSK3β (239-241). Also, insulin has been demonstrated to directly activate 
C/EBPβ in a PI3K-dependent manner (242). Despite its function as an activator of pro-
inflammatory gene expression, C/EBPβ can also negatively interfere with NFκB-mediated 
transcription by blocking phosphorylation of p65 (243). Therefore, one could argue that 
the observed opposing trend of insulin-regulated IL-6 mRNA expression with or without 
palmitic acid arises from differential activity of C/EBPβ. Nevertheless, further analysis of 
inflammatory cascade activation either by insulin alone or in combination with classic pro-
inflammmatory mediators is required to shed light on these processes.  
 
 
4.5.3 The Effects of Insulin on Macrophage Migration 
The ability to migrate towards loci of inflammation is a central feature of 
macrophage behaviour. In obesity, chronic inflammation in fat induces the local release of 
chemokines thereby attracting monocytes from the circulation to enter the tissue which 
subsequently differentiate into macrophages (157, 166). Proteases like plasminogen (Plg) 
and matrix metalloproteinases (MMPs) regulate leukocyte recruitment in inflammation by 
promoting extracellular matrix (ECM) degradation (244, 245). It was recently reported that 
matrix metalloproteinase 9 (MMP-9) is necessary to provide macrophage trans-ECM 
migration in inflammation and development of inflammation-associated diseases (246). 
Interestingly, insulin is able to regulate MMP-9 gelatinolytic activity in a MAPKinase-
dependent manner and thereby promotes migration of THP-1 monocytes (247, 248). In the 
current study we could show that insulin enhances MMP-9 gelatinolytic activity also in 
primary murine macrophages. Furthermore, it was demonstrated that insulin receptor-
deficient macrophages exhibit reduced MMP-9 gene expression in the presence of serum 
as well as after stimulation with palmitic acid. This implicates a macrophage-autonomous 
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impairment in ECM-remodeling and migration. Also, after preincubation with insulin, 
chemotaxis of macrophages from IR∆myel mice towards MCP-1 was significantly blunted 
compared to controls. These experiments provide an explanation for the reduced 
macrophage accumulation observed in adipose tissue of diet-induced obese IR∆myel mice. 
However, in vivo evidence for reduced gelatinolytic activity in adipose tissue or reduced 
circulating matrix metalloproteinase levels in IR∆myel mice is necessary to underline this 
argument.  
Notably, siRNA-mediated knockdown of Cap, which is involved in PI3K-
independent insulin-stimulated glucose uptake, leads to impaired motility of RAW264.7 
cells in vitro. Furthermore, bone marrow-specific deletion of Cap results in reduced 
obesity-induced macrophage accumulation in adipose tissue of mice (249). In combination 
with the current study, this underlines the crucial role for insulin in the obesity-induced 
infiltration of adipose tissue by macrophages. Intriguingly, these results imply a pivotal 
role for insulin-mediated glucose uptake in macrophages. The dependency of macrophages 
on hexoses as an energy source in the pro-inflammatory and microhypoxic environment 
encountered in obesity has been proposed before (174, 250-252). Hypoxia inducible factor 
(HIF) 1, the central regulator of the hypoxic response, and insulin share common target 
genes (253). Regulation of these genes is crucial to shift ATP production from the 
respiratory chain to anaerobic glycolysis thereby maintaining energy supply (254). Thus, 
the observed phenotype may originate from a fundamental energy problem encountered in 
insulin receptor-deficient macrophages. Further analysis of hexose metabolism in response 
to insulin, especially under conditions of hypoxia, hyperlipidemia and hyperglycemia, 
would provide valuable insight into macrophage function under obesity-associated stress 
conditions.  
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4.6 Conclusions 
Here, we highlight the importance of macrophages as an initiating cell type in the 
HFD-induced, pro-inflammatory insulin resistance cascade. The findings of the present 
study reveal an unexpected and pivotal role for insulin signal transduction in the control of 
innate immune cell behaviour in obesity-induced insulin resistance. Our study 
demonstrates for the first time in vivo that insulin, despite its positive effects on glucose 
metabolism in target tissues such as liver, skeletal muscle and adipose tissue, can develop a 
deleterious role in cell types that are not classically involved in metabolic signaling 
processes. Simulation of the obesity-associated lipidemia by administration of saturated 
fatty acids to macrophages demonstrates that lipocytotoxicity can eradicate large numbers 
of these cells in vitro. According to our results, high insulin levels might promote the 
protective signal to maintain macrophage populations in a pro-apoptotic environment in 
vivo. Thereby these cells can perpetuate their devastating behaviour by initiating 
inflammatory response mechanisms that ultimately induce insulin resistance. In addition, 
the beneficial effect of hyperinsulinemia on macrophage functions such as pro-
inflammatory gene expression and tissue infiltration could further contribute to the harmful 
role of these cells in obesity-induced insulin resistance. An intriguing question for future 
experiments is, whether myeloid cells from type 2 diabetic patients are resistant to insulin 
action. Further exploration of the interaction between metabolic signals and macrophage 
function offers a promising target for novel interventions in obesity-associated insulin 
resistance and type 2 diabetes mellitus. Additionally, several other diabetes-associated and 
macrophage-related diseases such as retinopathy, nephropathy, neuropathy and impaired 
wound healing represent interesting subjects for further investigation. 
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5 Summary 
A major component of obesity-related insulin resistance is the establishment of a 
chronic inflammatory state with invasion of white adipose tissue by mononuclear cells. 
This results in release of pro-inflammatory cytokines, which in turn leads to insulin 
resistance in target tissues such as skeletal muscle and liver. To determine the role of 
insulin action in macrophages and monocytes in obesity-associated insulin resistance, we 
have conditionally inactivated the insulin receptor (IR) gene in myeloid cells of mice 
(IR∆myel mice). While these animals exhibit unaltered glucose metabolism on a normal diet, 
they are protected from the development of obesity-associated insulin resistance upon high 
fat feeding. Euglycemic-hyperinsulinemic clamp studies demonstrate that this results from 
decreased basal hepatic glucose production and from increased insulin-stimulated glucose 
disposal in skeletal muscle. Furthermore, IR∆myel mice exhibit decreased concentration of 
circulating tumor necrosis factor (TNF) α and reduced c-jun N-terminal kinase (JNK) 
activity in skeletal muscle, reflecting a drastic reduction of the chronic and systemic low-
grade inflammatory state associated with obesity. This arises from reduced inflammatory 
recruitment of macrophages to white adipose tissue. Cell-autonomously, insulin receptor-
deficient macrophages are prone to lipid-induced apoptosis and exhibit reduced pro-
inflammatory gene transcription. Additionally, these cells show a pronounced impairment 
of lipid-induced matrix metalloproteinase (MMP) 9 expression and decreased motility in 
response to macrophage chemoattractant protein (MCP) 1. These data indicate that insulin 
action in myeloid cells plays an unexpected, critical role in the regulation of macrophage 
invasion into white adipose tissue and the development of obesity-associated insulin 
resistance. 
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6 Zusammenfassung 
Ein wichtiges Merkmal der Adipositas-assoziierten Insulinresistenz ist die Etablierung 
einer niedriggradigen aber chronischen Entzündung im Körper. Dieser 
Entzündungsprozess wird von einer Infiltration des weissen Fettgewebes durch 
Makrophagen begleitet. Das Resultat dieser Infiltration ist die lokale Ausschüttung 
proinflammatorischer Zytokine, die dann in die Blutbahn gelangen und eine 
Insulinresistenz in wichtigen Zielorganen der Insulinwirkung, u.a. Skelettmuskulatur und 
Leber, verursachen. Um die Rolle der Insulinwirkung auf Makrophagen und Monozyten 
im Zusammenhang mit der Adipositas-assoziierten Insulinresistenz zu untersuchen, haben 
wir das Insulinrezeptor (IR) Gen in myeloiden Zellen von Mäusen konditional inaktiviert 
(IR∆myel). Während diese Tiere unter Einfluss von Normaldiät einen unveränderten 
Glukosemetabolismus aufweisen, sind sie vor den verheerenden Konsequenzen einer 
fettreichen Diät auf die Insulinsensitivität geschützt. Dies ist auf eine verminderte basale, 
hepatische Glukoseproduktion und eine erhöhte, insulinstimulierte Glukoseaufnahme der 
Skelettmuskulatur zurückzuführen, was durch euglykämische, hyperinsulinämische Clamp 
Analyse demonstriert wurde. Darüberhinaus zeigen adipöse IR∆myel Mäuse reduzierte 
Tumor Nekrose Faktor (TNF) α Konzentrationen im Blut und verminderte Aktivität der c-
jun N-terminalen Kinase (JNK) im Skelettmuskel, was eine drastische Reduktion der 
Adipositas-assoziierten, chronischen Entzünding reflektiert. Dies resultiert aus einer 
verminderten inflammatorischen Rekrutierung von Makrophagen in das weisse 
Fettgewebe. Auf zellautonomer Ebene bewirkt das Fehlen des Insulinrezeptors in 
Makrophagen eine erhöhte Anfälligkeit für lipidinduzierte Apoptose und eine reduzierte 
proinflammatorische Gentranskription. Zusätzlich zeigen diese Zellen eine deutliche 
Beeinträchtigung der lipidinduzierten Expression von Matrix Metalloproteinase (MMP) 9 
und eine verminderte Motilität in Reaktion auf Makrophagen Chemoattractant Protein 
(MCP) 1. Diese Daten belegen, dass Insulin eine entscheidende und kritische Rolle in der 
Regulation der Infiltration von Makrophagen in das weisse Fettgewebe und der 
Entwicklung einer Adipositas-assoziierten Insulinresistenz spielen. 
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